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Bexarotene reverses alopecia in cutaneous T-cell
lymphoma
SIR, Mycosis fungoides (MF) is characterized by clonal
helper ⁄ memory (CD4+ CD45RO+) T-cells in the epidermis,
whereas follicular mucinosis or alopecia mucinosis has
perifollicular T-cell infiltrates and may clinically resemble
alopecia areata.1,2 Bexarotene is the first retinoid X receptor
(RXR)-selective retinoid shown to be effective for cutaneous
T-cell lymphoma.3,4 Bexarotene has recently been shown to
induce T-cell apoptosis in vitro.5 Although bexarotene oral
and topical gel are effective for MF, this is the first report, to
our knowledge, of reversal of associated alopecia.
Five patients with alopecia secondary to MF or follicular
mucinosis were observed among a cohort of over 90 patients
receiving bexarotene therapy at the M.D. Anderson Cancer
Center. Their demographic data, degree of hair loss, skin
biopsy results and drug administration are shown in Table 1.
The location of the hair loss was confined to the scalp in four
patients and to the extremities in a fifth. All of the skin biopsy
specimens revealed atypical CD4+ CD8+ perifollicular lympho-
cytic infiltrates, and two showed mucin deposits consistent
with follicular mucinosis. Three patients had scaling with
negative fungal cultures. Patients with early stage MF were
treated with topical bexarotene therapy and advanced stage
patients with oral bexarotene. The MF as well as the alopecia
improved in all five patients, irrespective of the route of
delivery. Hair regrowth began within 2–9 months and full
regrowth was evident by 1Æ5 years.
Patient 1. A 77-year-old Native American woman presen-
ted with a 3-month history of a single patch of alopecia
accompanied by pruritus and mild tenderness, generalized
xerosis, fatigue and a 4Æ5-kg unintentional weight loss.
Asthma and childhood eczema were noted. There was a
4 · 5 cm alopecia areata-like lesion with scaling on the scalp
(Fig. 1a) and macular erythema of less than 1%. An atypical
CD4+ CD8– clonal lymphocytic infiltrate and mucin deposits
were present in the follicular epithelium. After applying 1%
bexarotene gel daily to the leg and scalp lesions, partial
hair regrowth was present at 3 months (Fig. 1b), with full
regrowth of terminal grey hair covering the former patch of
alopecia at 5 months (Fig. 1c).
Patient 2. A 64-year-old Hispanic man with dermatitis for
30 years developed generalized exfoliative erythroderma,
patchy alopecia, and a skin biopsy consistent with MF. He
had increased fatigue, chills, night sweats and intense
pruritus. On examination, he had generalized exfoliative
erythroderma and lymphadenopathy. On the scalp, multiple
round alopecia areata lesions, patches of white hair, and
exclamation point hairs were observed (Fig. 2a,b). An atyp-
ical CD4+ CD8+ dermal infiltrate with epidermotropism and
a clonal T-cell receptor gene rearrangement were observed in
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the skin, and bone marrow and lymph nodes were also
involved. He was staged as IVa (T4N3B2M0) with Sézary
syndrome.
After 6 months on photopheresis without improvement, he
began a trial of oral bexarotene 450 mg daily (300 mg m)2
daily).3 Significant improvement of the skin lesions and
alopecia (partial response) was observed at 9 months. After
1Æ5 years on bexarotene therapy, his involved body surface
area had decreased from 100% to 1%, adenopathy had
resolved, and full hair regrowth and restoration of normal
hair colour was present (Fig. 2c,d). A complete clinical
remission at a reduced dose of 225 mg daily has been
sustained.
MF is characterized by a clonal proliferation of helper ⁄
memory (CD4+ CD45RO+) T cells in the epidermis, but
folliculotrophic variants are also described and lead to local or
more generalized alopecia.1,2 Alopecia areata, on the other
hand, has benign peribulbar clonal T-cell infiltrates that may
also be CD4+ and can downregulate epidermal proliferation
by production of interferon-c and tumour necrosis factor-a.6
Our work has shown that both diseases are associated with
HLA-DR5 and DQB1*03 alleles.7,8 In both MF and alopecia
areata, De Panfilis has hypothesized that activated T cells
become resistant to apoptosis, escape activation-induced cell
death (AICD) mediated through Fas ⁄ Fas ligand, and
accumulate in skin lesions.9 In the absence of AICD,
abnormal ⁄ malignant clones may evolve.
Retinoids control differentiation, proliferation and apoptosis
through interactions with tissue-specific retinoic acid receptor
RAR or RXR isotypes.10 Whereas RAR retinoids have
frequently been associated with the unwanted side-effect of
alopecia, we were surprised to observe the opposite in five MF
patients treated successfully with the first RXR-selective
agent, bexarotene. Rexinoids form heterodimers with other
steroid receptors, including thyroid, vitamin D, as well as
peroxisome proliferation-activating receptors that can down-
regulate the expression of inflammatory cytokines.11
Although bexarotene appears to be effective for treating MF
in both topical and oral forms,3,4,12 there are no other reports
of its effect on hair growth in either MF or alopecia areata.
While hair regrowth following other MF treatments is not
mentioned in the literature, and we have not personally
observed it with other standard MF treatments, systemic
steroids both induce T-cell apoptosis and are quite effective in
treating alopecia areata. Whether the hair regrowth in these
five patients was a direct result of reducing the T-cell
infiltrates or of other effects on hair follicles is unknown at
this time. Two phase II trials of topical and oral bexarotene for
alopecia areata and alopecia totalis, respectively, are in
progress to address this issue.
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Figure 1. Patient 1. (a) Large patch of alopecia with fine white scale
on crown of the scalp. (b) Partial hair regrowth after 3 months of
topical bexarotene therapy. (c) Almost full regrowth with terminal
grey hairs after 5 months of topical bexarotene therapy.
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Figure 2. Patient 2. (a,b) Multiple round
patches of hair loss with associated exclama-
tion point hairs and patches of white hair.
(c,d) Almost full hair regrowth and the pat-
ches of white hair returning to normal colour
after 18 months of oral bexarotene therapy.
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Immunohistological characterization of a Japanese
case of pityriasis rotunda
SIR, We describe a 25-year-old Japanese woman who was
diagnosed as having pityriasis rotunda (PR). She presented
with multiple, round, well-demarcated hyperkeratotic lesions,
approximately 7–10 cm in diameter, slightly brown in
colour, on the lateral side of both upper arms and lower
limbs (Fig. 1). The condition was otherwise asymptomatic,
the skin anomaly being present since her early childhood.
None of the other members of the family showed ichthyotic
lesions. In order to rule out the possibility of other skin
disorders with similar symptoms, a histological examination
was performed on both lesional and unaffected skin. Histo-
pathology of lesional skin revealed a moderate degree of
compact hyperkeratosis without a granular layer (Fig. 2a),
and follicular plugs were seen within hair follicles. Few
keratohyaline granules were detected in the affected areas by
electron microscopy, in keeping with the results of light
microscopy. However, ultrastructural observation of the
unaffected areas showed keratohyaline granules of normal
size and number in the granular layer (data not shown).
Immunohistochemical studies were performed on samples
of both lesional and unaffected skin. Both types of sample were
labelled identically by antihuman keratin 1 and 10, anti-
transglutaminase (TGase) I and anti-involucrin antibodies
(data not shown for keratin and TGase; Fig. 2g,h for
involucrin). However, there was a marked decrease in fil-
aggrin and loricrin expression in the affected skin (Fig. 2c,e).
An in situ TGase assay showed no differences between affected
and unaffected skin (data not shown). Results of routine
haematological and blood chemistry tests were normal.
Tumour marker screening tests and abdominal ultrasound
tests were negative. Culture and KOH tests for dermatophytes
in the scales taken from the lesions were negative.
PR is an uncommon keratinization disorder originally
described in Japanese subjects.1–3 It is characterized by
multiple, round or oval, sharply demarcated, scaling patches.
Although in previous reports this disease was considered to
be a form of acquired ichthyosis4,5 or the expression of a
systemic disorder,6–8 the clinical phenotype and histology of
the eruption resemble those of autosomal dominant ichthy-
osis vulgaris.1,2 In order to characterize the keratinization
disorders overlying PR and to assess their aetiology, we
examined the expression patterns of marker proteins in
epidermal differentiation.
The results of the examination showed that both the
affected and unaffected areas were labelled almost identically
by antihuman keratin 1 and 10, anti-TGase I and anti-invo-
lucrin antibodies. In contrast, there was a marked decrease in
filaggrin and loricrin expression in the affected regions.
Although there are few reports describing the immunohisto-
chemical features of PR, the localized downregulation of these
proteins indicates that the dysfunction of the terminal
differentiation process may play a significant role behind
the patchy formation of hyperkeratotic regions. Furthermore,
these findings also may serve as a useful diagnostic marker
for identifying PR.
To our knowledge, more than 180 cases of PR have been
reported worldwide.9,10 Hitherto, only one English report and
two Japanese reports2,3 have documented ultrastructural
studies in PR,10 in which no abnormalities could be found in
the shape, size or number of keratohyaline granules. In view
of the fact that the results of the other Japanese studies, while
not precisely duplicating our results, confirmed salient aspects
of our ultrastructural findings,2,3 the classification of PR into
two heterogeneous types, with or without abnormalities in
keratohyaline granules, is highlighted as a valid topic for
further inquiry.
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Figure 1. Clinical appearance of pityriasis rotunda. A round, sharply
demarcated, flat, uniformly scaly and hyperpigmented lesion is evi-
dent on the upper right thigh. Arrowheads indicate the margin of the
hyperkeratotic lesion.
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Figure 2. Histological and immunohistological findings from lesional (a,c,e,g) and unaffected (b,d,f,h) skin. (a,b) Haematoxylin and eosin
staining; (c,d), (e,f) and (g,h) show the immunohistochemistry of filaggrin, loricrin and involucrin, respectively, labelled with streptavidin, Alexa
594 conjugate (red) staining in cryosections of the biopsy specimens. Nuclear counterstaining was performed using 4,6-diamino-2-phenylindole
(blue). Antifilaggrin monoclonal antibody (Biomedical Technologies, Stoughton, MA, U.S.A.), antiloricrin monoclonal antibody (gift from Dr D.R.
Roop) and anti-involucrin monoclonal antibody (Neomakers, Union City, CA, U.S.A.) were used as the primary antibodies. Biotinylated goat
antimouse IgG antibody (ScyTek, Logan, UT, U.S.A.) was used as a secondary antibody. The sections were then incubated with Alexa 594
conjugate (Molecular Probes, Eugene, OR, U.S.A.). C, Cornified layer; G, granular layer; S, spinous layer. Scale bar ¼ 50 lm.
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Ciclosporin A-induced sebaceous gland hyperplasia
SIR, we report on two kidney transplant recipients who
developed pronounced hyperplasia of multiple sebaceous
glands under long-term treatment with ciclosporin A. Seba-
ceous gland hyperplasia (SGH) is a benign disorder charac-
terized by the development of multiple hyperplastic sebaceous
glands. They are clinically detected as disseminated epithelial
tumours that may occur as a congenital disorder, sporadically
in advanced age, in association with immunosuppressive
medication in transplant recipients, or as a sign of the Muir–
Torre syndrome.1
Since transplantation, both patients (a 33-year-old male
with a terminal kidney insufficiency due to Alport syndrome
who received a kidney transplant in 1991, and a 66-year-old
male with two kidney transplantations in 1978 and in 1991
due to renal shrinkage) have been receiving ciclosporin A and
prednisolone. Over the last 10 years, the daily doses of the
younger patient (73 kg) have been 2 mg kg)1 ciclosporin A
and 0Æ07 mg kg)1 prednisolone, and of the elderly patient
(61 kg) over the last 23 years, 2Æ5 mg kg)1 ciclosporin A and
0Æ06 mg kg)1 prednisolone. Nine years after initiation of the
immunosuppressive treatment, the younger patient recog-
nized multiple asymptomatic skin-coloured lesions on the
face, neck and chest that continuously increased in number.
The older patient recognized facial sebaceous gland hyperpl-
asia 7 years after the second kidney transplantation.
At admission, both patients demonstrated a seborrhoeic
facial skin with multiple—approximately 40—disseminated,
yellowish to skin-coloured, 1–5 mm large papules mainly on
the forehead, the nose, and the cheeks (Fig. 1). The younger
patient also presented hyperplastic sebaceous glands at the
décolleté and the oral mucosa.
Histological examination in both patients showed an abnor-
mal superficial localization of the sebaceous glands in the upper
dermis, enlargement of their volume, and characteristic mor-
phology which comprised a broad rim of increased numbers of
undifferentiated, proliferating sebocytes and only central clus-
ters of advanced differentiated to mature sebocytes (Fig. 2).
As sebaceous glands are mostly considered by dermatolo-
gists in association with acne and seborrhoea, the antipro-
liferative and sebostatic effects of isotretinoin and
antiandrogens have been extensively studied. In contrast,
little attention has been paid to compounds that enhance the
activity of sebaceous glands. Indeed, development of multiple
cutaneous tumours has often been associated with ciclosporin
A therapy.2,3 Although benign and malignant sebaceous
Figure 1. Multiple hyperplastic sebaceous
glands seen as yellowish to skin-coloured
papules disseminated over the entire forehead
and at the buccal area (detail) of a 33-year-old
kidney transplant recipient under long-term
ciclosporin A treatment.
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gland tumours are generally rare, 10–16% of organ trans-
plant recipients with long-term ciclosporin A treatment in
combination with corticosteroids develop SGH compared with
1% of a nonimmunosuppressed control group.2,4 Interest-
ingly, development of SGH has previously been considered
to be dose-dependent, being observed in patients receiving
5–10 mg kg)1 per day5 but not in patients treated with lower
doses.3 However, both our patients have been receiving only
low-dose ciclosporin A, 2–2Æ5 mg kg)1 per day. As in our
patients, only male transplant recipients have been repor-
ted.2,4,5 On the other hand, SGH has not been observed in
transplant recipient children, a fact that has been explained
due to the immaturity of the pilosebaceous unit in child-
hood.4 An association between the duration of ciclosporin A
treatment and the development of SGH can be recognized. In
the majority of cases, SGH occurred after a long period of
high-dose immunosuppressive therapy, after a minimum of
4 years.4–6 In our patients, the disease presented after 9 and
19 years of ciclosporin A treatment, respectively.
Other immunosuppressive drugs, like prednisolone or
azathioprine, have not been suggested to induce SGH in
transplant recipients.3,5,6 Therefore, we consider SGH under
ciclosporin A treatment to be a direct and causal effect of
ciclosporin A on the sebaceous gland rather than as a result
of immunosuppression.5 The histological findings in hyper-
plastic sebaceous glands reported in our work differ markedly
from the ones reported in patients with senile SGH.1 While in
senile SGH a reduced turnover occurs with low numbers of
differentiating, lipid-producing cells, in ciclosporin A-induced
SGH hyperproliferation of undifferentiated sebocytes and
inhibition of differentiation lead to multilayered basal cells
with only a few islands of differentiated sebocytes (differen-
tiation arrest).
On the other hand, an association between sebaceous
gland carcinoma and iatrogenic immunosuppression has
been reported recently, as sebaceous gland carcinomas may
be overrepresented in immunosuppressed renal transplant
patients.7 As in Muir–Torre syndrome, a microsatellite
instability in posttransplant sebaceous carcinoma DNA was
found together with a loss of mismatch repair genes,8
indicating a possible interaction between DNA mismatch
repair gene proteins and immunosuppressive drugs. Immu-
nosuppressive treatment may possibly unmask a latent Muir–
Torre syndrome or promote tumour progression in genetic-
ally susceptible patients.
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Figure 2. Histological findings of sebaceous
gland hyperplasia under long-term ciclosporin
A treatment. Sharply demarcated lobules of
enlarged sebaceous glands almost adjusted to
a thinned epidermis. The glands are separated
from the dermis by a cellular fibrous stroma
(fibrous pseudocapsule) (33-year-old patient).
Detail: higher magnification of a sebaceous
gland lobule shows that the sebaceous lobules
are composed of two major sebocyte popula-
tions: an unusually broad peripheral rim of
multilayered small, undifferentiated, prolifer-
ating sebocytes and aggregates of fully differ-
entiated to mature sebocytes with large
basophilic nuclei and abundant multivacuo-
lated clear cytoplasm in the centre. Original
magnification ·40, detail ·400.
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Disseminated cutaneous Mycobacterium haemophilum
infection with severe hypercalcaemia in a failed renal
transplant recipient
SIR, Mycobacterium haemophilum was first identified in 1978
from ulcerating skin lesions in a patient with Hodgkin’s
disease.1 More than 120 cases have been reported, mostly in
immunocompromised hosts such as AIDS patients and organ
transplant recipients.2 As it is a fastidious organism with
unique growth requirements, M. haemophilum infection is
usually underdiagnosed.3 We report a disseminated cutane-
ous M. haemophilum infection in a renal transplant recipient
who had chronic graft rejection necessitating haemodialysis.
Extensive cutaneous involvement and associated severe
hypercalcaemia were noteworthy features.
A 44-year-old Taiwanese man presented to our Dermatol-
ogy Clinics in October 2000 with a 10-week history of
progressive generalized asymptomatic skin rash, swelling of
the left eyelids and arthralgia. He had been on long-term
multiple immunosuppressants since cadaveric renal trans-
plantation in November 1991 due to end-stage renal failure.
In August 2000, immunosuppressive therapy was discontin-
ued because of graft failure, and he resumed haemodialysis
with normal calcium dialysate (Ca 2Æ5 mEq L)1). From July
2000, calcium carbonate 1Æ5 g three times daily was
prescribed, and in October the serum calcium rose to
11Æ9 mg dL)1 (normal 8Æ1–10Æ1).
Examination revealed swelling of the left eyelids and
multiple erythematous scaly patches and plaques, some
arcuate or annular in shape, over the upper and lower
proximal extremities. Histopathology of two skin biopsies
taken from the right arm and left upper eyelid showed
follicular hyperkeratosis, mild epidermal hyperplasia, exten-
sive infiltration of lymphocytes and epithelioid histiocytes, and
palisading granulomas in the upper dermis. Three weeks later,
drowsiness and general weakness associated with severe
hypercalcaemia (19Æ6 mg dL)1) were found, and two sessions
of emergency haemodialysis with low-calcium dialysate (Ca
1Æ25 mEq L)1) were initiated to normalize the serum calcium
level to 9Æ2 mg dL)1. Ultrasonography of the neck ruled out
any parathyroid lesion. There were decreased levels of intact
parathyroid hormone (i-PTH; 6Æ8 pg mL)1, normal 10–65),
elevated 1a, 25-dihydroxyvitamin D (127 n mL)1, normal
15Æ9–55Æ6) and parathyroid hormone-related protein
Figure 1. Mycobacterium haemophilum infection manifesting as (A) swelling of the left eyelids, (B) large annular erythematous scaly papules and
plaques on the upper proximal extremities, (C) ulcerative infiltrating plaques on the left calf, and (D) tender erythematous nodules on the fingers.
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(PTHRP; 9Æ98 pmol L)1, normal < 9Æ2), and normal 25-
hydroxyvitamin D (18Æ24 pg mL)1, normal 9Æ7–41Æ7).
During hospitalization, the skin lesions continued to
progress, with aggravating arthralgia. The left eyelids became
more swollen with some pustules (Fig. 1A). The arcuate or
annular lesions enlarged (Fig. 1B). There were erythematous
fluctuating ulcerative plaques dotted with pustules over the
right thigh and left calf (Fig. 1C). Multiple tender erythema-
tous papules, pustules and plaques appeared on the volar
sides of the fingers and dorsa of the hands, especially the
knuckles (Fig. 1D). Two further skin biopsies, taken from a
plaque and a pustule, showed pseudocarcinomatous epider-
mal hyperplasia, and suppurative and palisading granuloma-
tous dermatitis (Fig. 2A). Compared with previous skin
biopsies the inflammation was more extensive, with more
numerous multinucleated giant cells and neutrophils with
microabscesses, focal haemorrhage and necrosis in the
dermis. Numerous acid-fast bacilli were detected in all four
biopsy specimens by Ziehl–Neelsen stain, but cultures of the
draining pus for mycobacteria in Lowenstein–Jensen medium
and for common bacteria yielded negative results. A 435-bp
DNA fragment was amplified by polymerase chain reaction
(PCR) with the specific primer pair for the heat shock protein
65 gene (hsp65) of mycobacteria from all four paraffin-
embedded tissue specimens.4 Digestion of the amplicon by
BstEII and HaeIII revealed restriction fragments compatible
with the pattern of M. haemophilum (Fig. 2B),5 which was
confirmed by direct DNA sequencing. Chest computed
tomography showed a 0Æ4 · 0Æ3-cm well-defined nodule in
the right lower lobe of the lung.
Under the diagnosis of disseminated cutaneous M. haemo-
philum infection, antimycobacterial therapy was initiated
with clarithromycin 500 mg twice daily, ciprofloxacin
200 mg four times daily and rifampin 600 mg four times
daily. The skin lesions became more inflamed and oozing in
the first few weeks after commencing treatment, and then
gradually improved over the next 3 months with postinflam-
matory hyperpigmentation, scarring and milia formation.
The arthralgia also improved in parallel. Histopathology
performed 8 months following initiation of treatment showed
oedematous fibrosing granulation tissue and focal small
granulomas without evidence of acid-fast bacilli. Repeated
tissue culture under appropriate conditions for 8 weeks failed
to isolate M. haemophilum, and PCR demonstrated no further
hsp65 product.
Low-calcium dialysate was initially needed to maintain
normal serum calcium level, while normal-calcium dialysate
was used for haemodialysis 2 weeks after initiation of
antimycobacterial therapy. Follow-up after 1 year of treat-
ment showed normal levels of i-PTH (63Æ2 pg mL)1), 1a,
25-dihydroxyvitamin D (24Æ95 pg mL)1) and 25-hydroxy-
vitamin D (38Æ33 ng mL)1). The pulmonary nodule was no
longer detected.
Cultures remain the gold standard for the diagnosis of
M. haemophilum infection. Early correct diagnosis of the
infection is difficult if strict culture conditions are not
followed. The bacterium grows slowly at an optimal tem-
perature of 30–32 C in 5–10% CO2, as opposed to 37 C for
most other pathogenic mycobacteria.6 A medium supple-
mented with iron compounds such as ferric ammonium
citrate or haemin is needed.6 In our case, the initial culture
failed to grow M. haemophilum because the culture conditions
were not suitable for this organism. Fortunately, PCR study
was able to detect M. haemophilum DNA in the biopsy
specimens. As M. haemophilum is rarely detected by PCR in
our hospital, the possibility of contamination was small.
Mycobacterium haemophilum infection most commonly
affects the skin, manifesting as erythematous papules or
nodules that may become suppurative with painful draining
ulcers.3 Cysts, erythema, cellulitis, scaly plaques, focal
BA
Figure 2. (A) Histopathology of the third and fourth skin biopsies showed pseudocarcinomatous hyperplasia, severe suppurative and necrotizing
granulomatous dermatitis, microabscesses and focal haemorrhage (insert) with numerous acid-fast bacilli singly or in clusters (haematoxylin and
eosin, original magnification ·400; insert: Ziehl–Neelsen, original magnification ·1000). (B) Digestion of the amplicons from the four biopsy
specimens by BstEII and HaeIII revealed restriction fragments (BstEII: 325, 140 bp; HaeIII: 175, 115 bp) compatible with the pattern of Myco-
bacterium haemophilum.5 M, Marker ladders; B, BstEII; H, HaeIII.
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panniculitis and annular plaques have also been repor-
ted.3,6,7 Skin lesions may be localized or diffuse, and are most
often found on the extremities, especially over the joints.6
Uncommon extracutaneous manifestations include septic
arthritis, osteomyelitis6 and pulmonary nodules.3,8 Mycobac-
terium haemophilum infection in our patient was unusually
extensive, probably precipitated by chronic immunosuppres-
sive and uraemic status. Periorbital lesions and concurrent
joint and pulmonary involvement has rarely been described.6
Hypercalcaemia caused by extrarenal production of 1a,
25-dihydroxyvitamin D by granulomatous infiltrates has
been reported in various granulomatous diseases, but its
association with M. haemophilum infection has not been
documented in the English language literature.9 In our case,
the decreased i-PTH, normal 25-hydroxyvitamin D, but
elevated 1a, 25-dihydroxyvitamin D and PTHRP indicated
extrarenal production of the last two, which appeared to be
normalized by antimycobacterial therapy.
Disseminated infection with M. haemophilum requires sys-
temic antibiotics.6 The organism is usually sensitive to
ciprofloxacin, clarithromycin, rifabutin and rifampin, but
resistant to ethambutol, isoniazid and pyrazinamide in in vitro
tests.3,6 Treatment is recommended for at least 1 year.3 An
initial exacerbation of skin lesions at the beginning of
treatment, as seen in our patient, is not uncommon.3
To summarize, in immunocompromised or uraemic
patients, hypercalcaemia associated with extensive suppura-
tive and granulomatous cutaneous lesions with predilection
for the extremities should raise suspicion of M. haemophilum
infection. PCR analysis of the mycobacterial hsp65 gene can
be an effective tool for early identification of this infection.
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Juvenile pityriasis rubra pilaris: successful treatment
with ciclosporin
SIR, Pityriasis rubra pilaris (PRP), first described by Tarral in
1835, is an idiopathic, papulosquamous disease.1 Progression
of PRP can result in erythroderma with islands of sparing
(nappes claires). The age distribution is bimodal, with PRP
characteristically occurring during the first and fifth decades
of life. PRP affects both sexes, all races, and has been reported
worldwide. Most cases are acquired, although familial vari-
ants of the disease exist.2 Griffiths classified PRP into five
groups differing with respect to clinical features, course and
prognosis.2 Several therapeutic approaches for treating PRP
have been published, including vitamins, retinoids, antime-
tabolites, antibiotics and psoralen plus ultraviolet A.3 The use
of retinoids as first-line treatment of adult-onset PRP is well
established. However, childhood cases of PRP remain a
therapeutic problem.
A 4-year-old boy was admitted to the department of
dermatology with a 2-week history of an erythematous
eruption affecting the face. On examination, follicular papules
and plaques were found on the knees, elbows and axillae. The
palms and soles showed waxy-yellow diffuse hyperkeratosis
(Fig. 1). The patient’s medical history was unremarkable and
there was no personal or family history of skin disease. A skin
biopsy from the left axilla showed psoriasiform acanthosis,
alternating orthokeratosis and parakeratosis, and a moderate
lymphocytic perivascular infiltrate in the dermis. There was
no spongiosis and no microabscesses in the epidermis. The
boy was diagnosed clinically as having type III PRP and was
treated with topical, low-potency corticosteroids and urea
10% ointment. Within 4 weeks the PRP rapidly progressed to
result in erythroderma. At this time he was febrile with a
temperature of up to 39Æ5 C. Full blood count, erythrocyte
sedimentation rate, urea, electrolytes, liver function tests,
serum creatinine, serum iron levels, hepatitis profile, anti-
streptolysin-O antibodies and C-reactive protein were within
normal limits. He had no clinical symptoms or signs
suggesting an infection. Because of his poor condition,
treatment was initiated with oral ciclosporin 3Æ0 mg kg)1
daily and topical emollients. The thick scaly skin and
erythroderma dramatically regressed within 5 weeks. Serum
creatinine, serum urea nitrogen and blood pressure were
monitored regularly and remained within the standard range.
After clinical remission, the dose of ciclosporin was gradually
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tapered down to zero within 18 weeks. Complete clearance of
PRP was achieved with no recurrence for over 8 months.
PRP is marked by epidermal hyperproliferation with
abnormal keratinization, and dermal inflammation. Abnor-
mal vitamin A metabolism in the skin has been discussed for a
long time as a major cause of PRP, but convincing evidence
has not been provided. PRP has been observed after various
infections and trauma, but most cases occur without any
obvious preceding event.1 Documented cases of PRP in
patients with autoimmune disease or infection, e.g. with
human immunodeficiency virus, have led to speculation on a
possible underlying immune mechanism.4 Magro and Crow-
son5 hypothesized that the pathogenesis of PRP may be
related to an abnormal immune response to antigenic triggers.
Normally, juvenile PRP has a relatively rapid course and
resolves spontaneously within a year. Accordingly, poten-
tially harmful drugs should be used cautiously.6 However,
systemic treatment is necessary in patients with erythroderma
and disabling disease. The use of retinoids in prepubertal
patients, as recommended for adult-onset PRP, is problematic
on the basis of possible toxic effects on bone metabolism. In
this context, the short-term treatment of juvenile-onset PRP
with ciclosporin could be an alternative. Ciclosporin has been
shown to be a highly effective drug for the treatment of severe
inflammatory dermatoses in childhood.7 At present, the use
of ciclosporin for PRP has been reported only in adult-onset
cases, with conflicting results concerning its efficacy.8–12 In
our case, low-dose, short-term ciclosporin treatment resulted
in clearance of PRP within 5 weeks. The time-course suggests
that the improvement was due to the ciclosporin rather than
coincidental. Remission was achieved without hypertension
or adverse effects on renal function. During follow-up for over
8 months after withdrawal of ciclosporin there has been no
recurrence of PRP. The positive effects of ciclosporin in our
patient support the hypothesis of a possible underlying
immune mechanism for PRP. Ciclosporin therapy has poten-
tial side-effects such as nephrotoxicity, hypertension and
carcinogenesis, mainly after prolonged use. However, short-
term treatment with ciclosporin seems to be safe. We suggest
the use of ciclosporin in PRP patients with erythroderma and
disabling disease who have not responded to topical treat-
ment.
T . W e t z i g
M . S t i c h e r l i n g
Department of Dermatology,




1 Albert MR, Mackool BT. Pityriasis rubra pilaris. Int J Dermatol
1999; 38: 1–11.
2 Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5:
105–12.
3 Cohen PR, Prystowsky JH. Pityriasis rubra pilaris. A review of
diagnosis and treatment. J Am Acad Dermatol 1989; 20: 801–7.
4 Sanchez RM, Fuentes CG, Creus L et al. Pityriasis rubra pilaris and
HIV infection: a part of the spectrum of HIV-associated follicular
syndrome. Br J Dermatol 1995; 133: 818–9.
5 Magro CM, Crowson AN. The clinical and histomorphological
features of pityriasis rubra pilaris. A comparative analysis with
psoriasis. J Cutan Pathol 1997; 24: 416–24.
6 Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra
pilaris in childhood: a long-term study of 29 cases. Pediatr
Dermatol 1986; 3: 446–51.
7 Mahe E, Bodemer C, Pruszkowski A et al. Cyclosporine in child-
hood psoriasis. Arch Dermatol 2001; 137: 1532–3.
8 Meyer P, van Voorst Vader PC. Lack of effect of cyclosporin A in
pityriasis rubra pilaris. Acta Derm Venereol (Stockh) 1989; 69:
272.
9 Ghazi A, Laso-Dosal F. Cyclosporin A and pityriasis rubra pilaris.
Acta Derm Venereol (Stockh) 1990; 70: 181.
10 Gupta AK, Ellis CN, Nickoloff BJ et al. Oral cyclosporine in the
treatment of inflammatory and noninflammatory dermatoses. A
clinical and immunopathologic analysis. Arch Dermatol 1990;
126: 339–50.
11 Rosenbach A, Lowe NJ. Pityriasis rubra pilaris and cyclosporin.
Arch Dermatol 1993; 129: 1346–8.
12 Usuki K, Sekiyama M, Shimada T et al. Three cases of pityriasis
rubra pilaris successfully treated with cyclosporin A. Dermatology
2000; 200: 324–7.
Figure 1. Waxy-yellow diffuse hyperkeratosis of palms.
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Neurogenic pruritus: a case of pruritus induced
by transverse myelitis
SIR, Pruritus without a primary skin eruption generally
indicates an underlying medical disorder.1 Pruritus is a well-
known complaint in some medical illnesses such as choles-
tasis, uraemia, diabetes mellitus, malignancy, lymphoma,
polycythaemia vera and other myeloproliferative disorders.
Neurogenic pruritus is rare. We report the first case of
pruritus induced by transverse myelitis, an uncommon
neurological condition which initially presents with bilateral
lower extremity weakness, sensory loss with a distinct
dermatomal distribution, and urinary retention.2
A 43-year-old black woman initially presented with pain
and paraesthesiae in her legs. Three weeks after initial
presentation, she complained of terrible pruritus and hyper-
aesthesia of a well-demarcated area of her proximal upper
extremities, associated with difficulty in urinating. The
pruritus and allodynia were so severe that they prevented
her from falling asleep at night. Intravenous and oral
medications, including steroids, hydroxyzine, doxepin and
moisturizers, did not alleviate the symptoms. Oxycodone,
however, was an effective analgesic for her pain and pruritus.
Our patient’s past medical history was unremarkable. She
reported no history of any other medical problems including
multiple sclerosis or nerve tumours, recent upper respiratory
tract infection or recent vaccinations.
Physical examination revealed well-defined, hyperpigmen-
ted, lichenified plaques with pink excoriations present on the
lateral aspect of both upper extremities distal to the deltoid,
consistent with the C3-5 dermatomal distribution. Sensory
examination was significant for hyperaesthesia and allodynia
of the lichenified areas. Motor examination was normal.
Laboratory data, including full blood count, electrolytes, liver
function tests, thyroid-stimulating hormone, vitamin B12,
human immunodeficiency virus, Venereal Disease Research
Laboratory test, antinuclear antibody and cerebrospinal fluid
studies, were all normal. An electromyographic study was not
revealing. However, magnetic resonance imaging of the
cervical spine revealed an oval-shaped, hyperintense region
extending from C2-3 to C5-6 in the T2 weighted images,
which enhanced with gadolinium (Fig. 1). This image is
consistent with transverse myelitis of the spinal cord. Our
patient was observed for a period of months. Her symptoms of
pruritus and allodynia gradually abated as the transverse
myelitis resolved.
Neurogenic pruritus is an uncommon cause of pruritus, but
must be considered when pruritus follows a dermatomal
distribution. Other central nervous system lesions that may
cause localized pruritus include stroke,3 basilar artery
aneurysm,4 brain tumours5 and brain abscesses.6 In many
of these cases of central neurogenic pruritus, the affected
pruritic area was also either hypoaesthetic or hyperaesthetic,
findings which may help the clinician distinguish cases of
central neurogenic pruritus.
The physiological basis for pruritus has not yet been
completely worked out. Several observations and studies
support the hypothesis that pruritus is a submodality of
pain.7 The sensation of itch is thought to originate from the
nerve endings of myelinated delta A fibres and unmyelinated
C fibres near the dermoepidermal junction.8 Physiological
itch is believed to be transmitted by the rapidly conducting
myelinated delta A fibres, whereas unmyelinated C fibres in
the dermis that transmit pain are thought to transmit the
sensation of pathological or unpleasant pruritus, as well as
pain.7
Our patient’s pruritus was probably not caused by the tra-
ditional peripheral mediators such as histamine and the
endopeptidases,8 but by a pathophysiological process in
the spinal cord. The exact mechanism by which our patient
experienced pruritus is not clear, but it is interesting that only
Figure 1. Magnetic resonance imaging of the cervical spine reveals
an oval, hyperintense region extending from C2-3 to C5-6 in the T2
weighted images, which enhanced with gadolinium.
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opioids relieved her pruritus. The observation that itching
occurs with opioid spinal analgesia seems to indicate that the
spinal cord or the spinal roots are involved in the pruritic
effect. Whether the itch is due to a direct effect of the opioid,
or whether it lowers the threshold to other stimuli, is not
known.9
This report of transverse myelitis of the cervical spinal cord
inducing pruritus is, to our knowledge, the first report of
transverse myelitis causing pruritus. Importantly, the affected
pruritic area was hyperaesthetic, a finding which may help
the clinician distinguish cases of central neurogenic pruritus.
Our patient’s pruritus was not caused by the traditional
peripheral mediators such as histamine and the endopeptid-
ases, but by a pathophysiological process in the spinal cord,
which resulted in pruritus, with subsequent lichenification
caused by scratching. The exact mechanism by which our
patient experienced pruritus is not clear, but it may have been
caused by interruption of a yet undefined spinal pathway that
is capable of modulating the sensations of pain and pruritus.
Only opioids relieved her pruritus, and it is possible that
oxycodone, the opioid that relieved our patient’s pain, may
have modulated the spinal cord’s ability to transmit the
sensation of pruritus.
L . D . B o n d J r
G . C . K e o u g h *
Department of Dermatology, New
York Medical College, Valhalla, New
York, NY, and *Knoxville, TN, U.S.A.
E-mail: drbond_2000@yahoo.com
References
1 Beare JM. Generalized pruritus. a study of 43 cases. Clin Exp Der-
matol 1976; 1: 343–52.
2 Plum F, Olson ME. Myelitis and myelopathy. In: Clinical Neurology
(Baker AB, ed.), Vol. 3. Hagerstown, MD: Harper & Row, 1997:
24–49.
3 Massey EW. Unilateral neurogenic pruritus following stroke. Stroke
1984; 15: 901–3.
4 Shapiro PE, Braun CW. Unilateral pruritus after a stroke. Arch
Dermatol 1987; 123: 1527–30.
5 King CA, Huff J, Jorizzo JL. Unilateral neurogenic pruritus: parox-
ysmal itching associated with central nervous system lesions. Ann
Intern Med 1982; 97: 222–3.
6 Sullivan MJ, Drake ME. Unilateral pruritus and Nocardia abscess.
Neurology 1984; 34: 828–9.
7 Kunkle EC, Chapman WP. Insensitivity to pain in man: a research.
Nev Ment Dis Processes 1943; 23: 100–9.
8 Herndon JH. Itching: the pathophysiology of pruritus. Int J Der-
matol 1975; 14: 465–84.
9 Scott PV, Fischer HBJ. Spinal opiate analgesia and facial pruritus: a
neural theory. Postgrad Med J 1982; 58: 531–5.
Early apoptosis plays an important role in the healing
mechanism of cutaneous basal cell carcinomas
after photodynamic therapy
SIR, Topical photodynamic therapy (PDT) with d-5-amino-
laevulinic acid (5-ALA) is increasingly used in precancerous
skin lesions (actinic keratoses) and nonmelanoma skin cancer
[superficial basal cell carcinoma (BCC); Bowen’s disease].1
The mechanism of PDT depends on the activation of a
photosensitizing compound by visible light of an appropriate
wavelength that correlates with the absorption spectrum of
the photosensitizing compound in the presence of molecular
oxygen. The exogenous prodrug 5-ALA is converted intra-
cellularly to the endogenous photosensitizer protoporphyrin
IX, with preferential accumulation in neoplastic ⁄ dysplastic
tissue and consequent absorption of photons.2 This latter
results in a cascade of events, in which apoptosis has been
suggested to play an important role.3
In the present study, we have investigated the possible role
of apoptosis by the sequential analysis of lesional skin after
5-ALA-PDT (5-ALA in a 20% oil-in-water emulsion under
occlusion, and visible light by the lamp Fotoec 3 H250, Loto,
Florence, Italy: wavelength within the 630-nm range) in
eight patients with superficial BCC after informed consent.
The neoplastic skin samples were collected 15 min and 4, 24,
48 and 72 h after the irradiation in order to investigate the
possible modifications at the cellular and subcellular level (by
electron microscopy), the expression of apoptotic markers
[alkaline phosphatase–antialkaline phosphatase (APAAP)
and terminal deoxynucleotidyl transferase-mediated deoxy-
uridine triphosphate nick end labelling (TUNEL) methods],
and the immunophenotypic profile of the inflammatory cell
infiltrate (APAAP).
At 15 min after PDT, cells positive for annexin V, which
labels apoptotic cells after the phosphatidylserine transloca-
tion to the outer leaflet of plasma membranes and is
considered an early marker of apoptosis,4,5 were already
found in the neoplastic lobules and the overlying epidermis.
The largest amount of annexin V+ cells was found at 4 h
(Fig. 1). Later on, annexin V expression progressively and
clearly diminished until it disappeared. Fas and its ligand FasL
were expressed slightly at 15 min, showed much greater
expression at 4 h, and were progressively lost there-
after. These results are in agreement with others from the
Figure 1. Four hours after photodynamic therapy. Cells expressing
annexin V within the neoplastic lobules (alkaline phosphatase–anti-
alkaline phosphatase; original magnification · 200).
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literature,6 which showed a significant time-dependent
increase in the expression of Fas and FasL until 60 min after
PDT, followed by a progressive decrease thereafter. TUNEL
staining7 also showed a progressive increase of apoptotic
cells, starting at 15 min and reaching a maximum at 24 h,
followed by rapid disappearance thereafter.
By electron microscopy, clear-cut morphological signs of
apoptosis (cytoplasmic and nuclear condensation, margin-
ation of chromatin and intercellular oedema) were already
shown by basal keratinocytes at 15 min; at later time-
points, these modifications were also found at progres-
sively upper epidermal levels. At 24 h, organelle remnants
and cell membrane interruptions (later signs of apoptosis)
were observed. Interestingly, at this time-point mitotic
figures were found in the basal cell layer at the edge of
the specimen (Fig. 2), indicating the start of the re-
epithelialization process. Regarding the expression of Bcl-2
protein, which generally has a protective role in PDT-
induced apoptosis and is uniformly expressed by all
neoplastic cells in BCC,8 this was already reduced at
15 min, in line with the hypothesis of an early activation
of apoptotic pathways.
Regarding the time-related sequence of cell types infil-
trating neoplastic BCC tissue and overlying epidermis after
the treatment, this was overall as expected: mast cells at
the very beginning (15 min), mostly polymorphonuclear
granulocytes up to 24 h, and progressive infiltration by
CD3+, CD4+ lymphocytes (driving the late stage of the
apoptotic pathway) and CD68+ macrophages (mainly
devoted to removing apoptotic bodies by phagocytosis)
thereafter.
In conclusion, in full agreement with data from the
literature,9,10 our results seem to indicate that apoptosis
plays an important role in the healing mechanism of
superficial BCC after PDT, in keeping with the clinically
observed type of healing: few, if any, signs of acute inflam-
mation and definitely no necrosis of the lesion.
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Dead Sea extract sold under-the-counter
SIR, Atopic eczema and other chronic skin diseases are
conventionally treated with topical corticosteroids, but sys-
temic corticosteroids are also sometimes used. Some patients
do not always use the prescribed medication but seek other
remedies. One reason for this is fear of side-effects, e.g. from
corticosteroids. Complementary medicine is becoming
increasingly popular, particularly among patients with
long-standing conditions such as eczema, where conven-
tional medicine has not provided satisfactory solutions.1 The
most frequently used treatment modalities comprise homoe-
opathy, herbalism and food supplements.1–3 Patients tend to
Figure 2. Electron microscopy. Twenty-four hours after photody-
namic therapy. A mitotic figure in the basal epidermal layer (original
magnification ·15 000).
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regard herbal remedies as natural products without side-
effects.4 However, undeclared potent corticosteroids have
been found in Chinese herbal creams.4,5
In spring 1998 a woman with severe atopic eczema
enthusiastically reported to her clinician (A.B.) about the
prompt effect of the cream Psorial, which, according to the
label, has a Dead Sea extract as the active component,
obtained in a local health food shop. Psorial was also sold in
Denmark and an analysis of the cream performed at the
Danish Miljöstyrelsen showed it to contain two undeclared
corticosteroids, triamcinolone acetonide and halcinonide,
both in therapeutic concentrations.6
One year later, another patient visited A.B. with severe
perioral dermatitis. She had used a cream that seemed identical
to Psorial, because it was said to contain a Dead Sea extract,
but in this case the jar was unlabelled. We suspected that the
cream contained corticosteroids and therefore analysed it
using high-performance liquid chromatography according to a
previously reported procedure.7 The chromatogram showed
two peaks, with retention times corresponding to those for
triamcinolone acetonide and halcinonide. When triamcino-
lone acetonide and halcinonide were added to the sample, both
peaks increased in height, indicating that the sample contained
triamcinolone acetonide and halcinonide. The presence of
triamcinolone acetonide and halcinonide was verified by liquid
chromatography ⁄ mass spectrometry analyses. The calculated
concentrations of triamcinolone acetonide and halcinonide in
the cream were 0Æ12% and 0Æ13%, respectively.
This is not the first time over-the-counter products have
been found to contain wilfully added corticosteroids. Several
reports in the medical literature give evidence of this. The
Skin-Cap intended for treatment of psoriasis contained
clobetasol propionate,8,9 Psorial cream, meant for treating
psoriasis and atopic dermatitis, contained both triamcinolone
acetonide and halcinonide in therapeutic concentrations,6
and eight of 11 Chinese herbal creams contained dexameth-
asone.4 The most recent report is a warning against a cream
called Wau Wa Cream. Chemical investigations showed it to
contain clobetasol propionate.10
The two corticosteroids detected in our cream were both
present in therapeutic concentrations, which means that use
of the product could have led to unwanted side-effects had the
cream been used ad libitum without medical advice. In our
case, the jar containing the cream was unlabelled and our
patient had used the cream daily for a long period, resulting
in severe perioral dermatitis. When one of the investigators
(A.B.) tried to buy another jar at the health food shop where
the patient had obtained her sample, she was refused,
probably because she started asking questions.
As has been the case with Chinese herbal creams, Psorial
cream and the unlabelled Dead Sea extract cream were
marketed by word of mouth as safe and corticosteroid free. The
creams were used by adults as well as children for long periods
to treat different skin diseases. Not only were they hazardous
because of the potential side-effects due to the content of
potent corticosteroids, but they were also very expensive. As
many people with chronic skin diseases tend to turn to
complementary medicine, we wish to stress once again that
we must be suspicious of over-the-counter products with
unexpectedly but miraculously good clinical effects.
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Tazarotene 0Æ1% gel for psoriasis of the fingernails and
toenails: an open, prospective study
SIR, Nail psoriasis is reported in 10–55% of adults with
psoriasis, is uncommon in children (7–13%) and is more
frequent (up to 80%) in psoriatic arthritis.1 Its clinical
presentation is dependent on which part of the nail apparatus
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is affected (matrix, nail bed, nail plate, periungual skin).
Clinical signs include oil spots (yellowish or pinkish nail bed
discoloration surrounded by an erythematous halo), pitting
(irregular, nongeometrical depressions on the nail plate),
onycholysis (detachment of the nail plate from the nail bed),
subungual hyperkeratosis (hyperparakeratosis of the nail
bed), ridging (Beau’s lines, trachonychia), thickened and
brittle nails, splinter haemorrhages and paronychia.1 Oil
spots, pitting, onycholysis and subungual hyperkeratosis are
considered specific signs, with only the oil spots being strictly
diagnostic for psoriasis, whereas thickened and brittle nails,
splinter haemorrhages and paronychia are considered non-
specific. Psoriatic onychodystrophy and its response to
therapy are not related to the extent or severity of cutaneous
involvement. Treatment of nail psoriasis is motivated by
cosmetic problems, dysfunction or restriction in daily activ-
ities, or pain, as experienced by most patients. Besides
systemic drugs, therapeutic options include corticosteroids,2
vitamin D3 derivates,
3 5-fluorouracil,4 urea,4 dithranol,5
ciclosporin6 and radiotherapy.7 Tazarotene has recently been
used successfully for fingernail psoriasis.8 This drug is
approved for treating psoriasis, acne, photoageing, precan-
cerous lesions and established cancers.9
We performed a randomized, open study to evaluate the
effectiveness of tazarotene 0Æ1% gel on unoccluded psoriatic
fingernails and toenails. Thirty-five psoriatic patients with
significant onychodystrophy were enrolled, of whom 25 (20
men and five women, age range 22–66 years) completed the
present study. Four patients were withdrawn for protocol
violation and six were started on systemic therapy because of
worsening of the concurrent cutaneous condition. The mean
duration from the onset of psoriasis was 5Æ7 years. There was
a 12-week washout period for topical and systemic medica-
tions. Onychomycosis was excluded by direct microscopy and
culture. Tazarotene 0Æ1% gel was applied topically, without
occlusion, to the affected nail plates, surrounding nail folds
and periungual skin, at bed time, for a 12-week period.
Outcome measures were assessed at baseline and at 4, 8 and
12 weeks. Follow-up evaluations took place 12 and 24 weeks
after the end of treatment. Each fingernail and toenail was
clinically scored using a simple rating scale,7 the Visual
Assessment Score (0, normal; 1, moderately affected; 2,
severely affected), for each of the specific and nonspecific signs.
Nineteen of 25 patients showed a good clinical response.
The specific signs showed a statistically significant Visual
Assessment Score reduction after 12 weeks of application
(P < 0Æ0001), when compared with the mean pretreatment
score, and the nonspecific signs demonstrated substantial
clinical improvement (Table 1, Figs 1 and 2). The results
were observed in both fingernails and toenails, the initial
changes being detectable in the fingernails after only
4 weeks. Among the clinical signs, hyperkeratosis and oil
spots showed better and faster improvement, whereas pitting
seemed to be most persistent. The tolerability was reported by
the patients as excellent (74%), good (13%) and poor (13%),
this latter group mostly having toenail involvement. Mild
erythema (70%), peeling of the proximal nail fold (15%) and
Table 1. Mean Visual Assessment Score at baseline and after






Oil spots 18 3*
Pitting 13 1*
Nonspecific signs
Thickened ⁄ brittle nails 20 3
Paronychia 7 0
Splinter haemorrhages 1 0
*P < 0Æ0001. Statistically significant clearing (P < 0Æ0001) of the
specific signs and substantial improvement of the nonspecific signs
were seen after 12 weeks of tazarotene application. Statistical ana-
lysis was performed using the SPSS program (Statistical Package for the
Social Sciences, 5th edn, M. J. Norusis ⁄ SPSS Inc., Chicago, IL, U.S.A.).
For each parameter the mean, SEM and range were calculated.
Differences were evaluated by the t-test and nonparametric Mann–
Whitney U-test; P < 0Æ05 was considered statistically significant.
Figure 1. (a) The fingernails show evident hyperkeratosis, onycho-
lysis, pitting and oil spots at baseline. (b) Clearing of the clinical signs
after 12 weeks of tazarotene application.
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burning (15%) were the side-effects reported. Most patients
(60%) estimated the efficacy of the treatment as good.
After 24 weeks of follow-up, moderate recurrences were
observed, mainly as mild relapsing hyperkeratosis. Even
though assessment of the therapeutic response was based on
a visual score without an objective measurement of the nail
changes, the results of our 4-month study indicate that topical
self-application of tazarotene 0Æ1% gel without occlusion in
the evening is effective, well tolerated, and not time-consu-
ming. Spontaneous remission is possible during the course of
the disease, but the timing and degree of clinical responses
observed in our series were strongly suggestive of a causative
effect between tazarotene application and improvement of
most of the nail signs. The results obtained were not related to
the extent of skin involvement with psoriasis (data not
shown). Our study extends to the toenails the study by Scher
et al.8 who reported a randomized, double-blind, vehicle-
controlled study of tazarotene treatment of fingernail psoriasis.
Tazarotene is a synthetic acetylenic retinoid that is selective
for b and c isotypes of the retinoic acid receptor.9 This drug
acts on proliferation, differentiation and apoptosis of kera-
tinocytes and modulates inflammatory cells, processes which
are all known to be involved in the pathogenesis of
psoriasis.10 It may be assumed that tazarotene exerts its
action on psoriatic matrix and nail bed cells. To assure an
increase absorption, even in unoccluded nails, we suggest
careful application of tazarotene to the nail plate and the
surrounding periungual skin, including the nail folds and, to
increase patient compliance, provision of detailed information
on the common but usually moderate side-effects of tazaro-
tene.
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Stigmatization and psoriasis
SIR, We read with interest the article by Vardy et al.1
reporting increased experiences of stigmatization for psoriasis
patients over a comparison group of other dermatological
conditions. Experiences of stigmatization were found to
mediate the impact of severity of psoriasis on quality of life
for these individuals. Such an effect was not demonstrated for
Figure 2. (a) Mainly hyperkeratotic toenails are seen at baseline. (b)
Substantial improvement after 12 weeks of therapy.
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the comparison group. The paper recognizes the psychosocial
impact of psoriasis and highlights the need to consider
options beyond those available in the pharmacy when
managing patients with the disease. This view is encouraging
and is commensurate with findings and recommendations
from our work.2 Both research groups highlight that percep-
tions of stigmatization, along with depression, are the most
important variables in predicting everyday disability for
patients with psoriasis.
Given that a major component of stress experienced by
patients with psoriasis is due to both anticipation of the
potential for stigmatization as well as to actual experiences of
discrimination by others,2–4 we need to ask what can be done
to moderate the effects of such experiences. At an individual
level we report a 32-year-old man with a 15-year history of
psoriasis who presented with social anxiety. He was referred
by a consultant dermatologist due to high levels of social
avoidance because of his psoriasis. At initial assessment the
severity of his psoriasis on the Psoriasis Area and Severity
Index (PASI) was 3Æ9, with plaques located on his elbows,
trunk and scalp (PASI range 0–72; PASI > 12 ¼ severe
psoriasis). At clinical assessment he reported a high degree of
anticipatory anxiety and social avoidance. These difficulties
were related specifically to fears of being questioned, humi-
liated or rejected because of his psoriasis. He had never
previously encountered any actual experiences of stigmatiza-
tion because of his psoriasis. As research suggests,4 the fear of
being stigmatized and humiliated contributed to him enga-
ging in avoidance coping behaviours and thus aborting his
social plans. Such avoidance behaviour served to maintain
his difficulties by preventing him from experiencing any
positive nonstigmatizing social encounters. He underwent
seven sessions of cognitive–behavioural therapy focusing on
managing appraisals, misinterpretations and maladaptive
beliefs about his psoriasis and its potential consequences in
everyday life. Self-report measurements were taken at each
appointment in relation to perceptions of being stigmatized,
social anxiety and social avoidance (the therapist was blind
to these ratings). Linear regression analysis indicated a
significant linear trend over the course of treatment for
perceived stigmatization (F ¼ 8Æ29, P < 0Æ05), social anxiety
(F ¼ 6Æ19, P < 0Æ05) and social avoidance (F ¼ 16Æ30,
P < 0Æ01). Additionally, global improvements were shown
on the Psoriasis Disability Index (PDI) between baseline
(PDI ¼ 7) and end of treatment (PDI ¼ 0). In line with this,
at clinical interview the patient described being less socially
anxious and had engaged in social activities that he had
previously avoided. The improvements on these parameters
at an individual level correspond with those reported in our
recent controlled trial.5 In this trial a 6-week group cogni-
tive–behavioural psychological approach for patients with
psoriasis significantly improved anxiety (P ¼ 0Æ001), depres-
sion (P ¼ 0Æ001), psoriasis-related stress (P ¼ 0Æ001) and
disability (P ¼ 0Æ04), in addition to improving severity of
psoriasis as assessed by PASI (P ¼ 0Æ001), in comparison
with patients continuing with standard pharmacological
treatment alone.5 This work further highlights the utility
of psychological approaches, in particular cognitive–beha-
vioural therapy, in the management of psychological aspects
of psoriasis.
Such cognitive–behavioural approaches are perhaps lim-
ited by the availability of appropriate healthcare services.
Department of Health initiatives have recently been instiga-
ted to tackle the stigma and discrimination associated with
mental health difficulties. Perhaps we can learn from
research conducted in antistigma campaigns in the U.S.A.
These antistigma programmes tend to be of three main
types: media protest, where healthcare professionals, patient
groups and patient charities protest at inaccurate or
unhelpful media portrayals of, for instance, disfiguring skin
conditions; education, where information is provided to
counteract unhelpful stereotyping of stigmatized groups; and
contact, where members of the public meet people from
stigmatized groups so that inaccurate and stigmatizing
assumptions can be challenged and changed. Research on
people who have been given diagnoses such as anxiety,
depression or other mental health difficulties demonstrates
the superiority of contact in reducing stigma and discrim-
inating attitudes.6 Clearly further research is needed to
highlight how best to integrate the targets of such
campaigns into clinical practice.
Psoriasis is a stigmatizing condition. Patients with psoriasis
may have to contend with stigma arising from uninformed
public attitudes to psoriasis as well as feelings of stigma that
may arise from such discrimination. Given the clear difficul-
ties associated with the management of psoriasis, stigma,
either perceived or actual, has major implications for health-
care. As such, and given the data presented by Vardy et al.1
and ourselves,2 we need to move forward from mere
consideration of a biopsychosocial approach in the manage-
ment of psoriasis to embracing it fully in our assessments and
interventions.
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Suggestions for uniform outcome variables
when reporting treatment effects in hidradenitis
suppurativa
SIR, Hidradenitis suppurativa (HS) is a chronic recurrent
disease causing inflammation, suppuration and scarring of
inverse areas, i.e. the axilla, groin or inframammary folds.1
Treatment consists mainly of surgery, while medical therapies
principally serve as adjunct therapy.2,3 Randomized con-
trolled trials (RCT) in HS have, however, found that cypro-
terone acetate and ethinylestradiol, topical clindamycin and
tetracycline may all be useful.4–6
Surgical technique does not lend itself to the concept of
RCT, and large cohort studies therefore represent the best
level of evidence for surgical procedures. In order for such
a cohort to be established, uniform outcome variables must
be used. Having reviewed the papers on the surgical
treatment of HS, the HS European Research Group (HISERG)
found great variation in the reporting of results, making
comparison of techniques difficult, e.g. between radical
surgery involving the excision of large areas of potentially
involved skin and less extensive invasive techniques.
Several inherent features of HS are commonly omitted
from reports of treatment outcomes: lag time for recur-
rences is often only reported for groups, and no distinction
is made between the sites of new elements, making it
impossible to distinguish true recurrence from new disease.
The location of recurrent disease is rarely given, e.g. local
vs. regional vs. extraregional. Treatment has not failed if a
new lesion appears in a previously untreated region.
Treatment may prevent acute lesions but leave chronic
lesions unaffected.
In the classic Hurley clinical grading system, stage I
consists of one or more abscesses with no sinus tract or
cicatrization, and stage II consists of one or more widely
separated recurrent abscesses, with a tract and scarring. The
most severe cases (stage III) are described as having multiple
interconnected tracts and abscesses throughout the entire
affected area. The Hurley grading system is very useful for
overall classification of cases and may form the basis for
selection of appropriate treatment in a selected anatomical
region. Milder cases are often manageable with medical
therapy, Hurley II cases need local surgery including carbon
dioxide laser treatment with secondary-intention healing,
while Hurley III cases generally require wide surgical excision
of the entire affected region.
One of the major interests of the HISERG is to perform
multicentre clinical treatment studies in order to have studies
of sufficient statistical strength in HS. In this context, we have
found that the Hurley staging system is not sufficiently
dynamic for assessing differences in treatment effects.7
Among HS patients seeking help from dermatologists for
their disease, cases graded as Hurley II form the majority, and
within this common disease stage group there is a wide
variation of clinical findings and symptoms. Milder cases with
comparatively small problems exist in this group, while the
more severe cases graded as Hurley II may have debilitating
symptoms. It is therefore important to develop a more
dynamic and precise scoring system for HS by adding clinical
details to the staging process.
Ideally, uniform outcome variables should take into
account the known characteristics of the specific disease.
In HS this suggests that reporting should allow for the
inherently multifocal nature of HS and the potentially long
time-to-recurrence lag. It is therefore proposed that the
following outcome variables are explicitly mentioned in
future reports:
1 Anatomical region involved (axilla, groin, gluteal or other
region or inframammary region left and ⁄ or right: 3
points per region involved).
2 Number and scores of lesions (abscesses, nodules, fistulas,
scars: points per lesion of all regions involved: nodules 2;
fistulas 4; scars 1; others 1).
3 The longest distance between two relevant lesions, i.e.
nodules and fistulas, in each region, or size if only one
lesion (< 5 cm, 2; < 10 cm, 4; > 10 cm, 8).
4 Are all lesions clearly separated by normal skin? In each
region (yes 0 ⁄ no 6).
By assigning numerical scores to these variables, disease
intensity can be quantified in a more clinically meaningful
way on an open-ended scale. A total score as well as scores of
selected regions chosen for surgical or other intervention can
be calculated and followed over time. In order to test this
suggested new scoring system for HS we have performed a
retrospective assessment using the proposed score in 34
patients previously carefully defined.2 The results are shown
in Table 1 and Figure 1, suggesting that the proposed system
may be of practical use.
Furthermore, as pain is an important feature of HS a
subjective evaluation should be included, preferably a visual
analogue scale score of pain from the worst lesion as chosen
by the patient.6 The suggested baseline scoring system may
be further improved by adding other subjective scoring
systems, e.g. the Dermatology Life Quality Index, in future
prospective trials.8 With the reporting of these parameters
the assessment of treatment outcome would be improved
Table 1. The results of evaluation of a new scoring system for





Total score 30Æ5 ± 24Æ2 12Æ0 ± 17Æ2
Regional score 11Æ4 ± 4Æ1 1Æ5 ± 3Æ6
For regional scores, representative regions treated with carbon
dioxide laser and healing by secondary intention were chosen.
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Figure 1. Representative pictures of hidradenitis suppurativa lesions. The regional score is given in parentheses. (a) A 26-year-old woman. The
opening of a 4 cm long fistula of the groin (7 points). (b) A 25-year-old woman. A nodule of the groin (5 points). (c) A 44-year-old man. A
combination of fistulas, scars and nodules of the armpit (37 points). This patient, graded as stage III according to Hurley, was not included in the
study. (d) A 36-year-old woman. Nodules of the armpit (19 points).
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significantly, aiding clinical management of this recalcitrant
disease and the development of new treatments.
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High-level ultraviolet A photoprotection is needed to
prevent doxycycline phototoxicity: lessons learned in
East Timor
SIR, Doxycycline is a commonly prescribed drug used to treat
a number of inflammatory skin conditions such as acne and
rosacea. As a member of the tetracycline group of antibiotics,
it is a well-tolerated drug with occasional side-effects such as
gastrointestinal irritation and vaginal candidosis. Rarer side-
effects of doxycycline therapy include nonspecific drug
rashes, phototoxic reactions and photoonycholysis. Photo-
toxic eruptions are thought to be due to radiation in the long
wavelength ultraviolet (UV) A1 spectrum (340–400 nm) and
appear to be dose dependent.1 Incidence reports in the
literature range from 3%2 to 10%3 in those taking doxycy-
cline 100 mg daily.
Doxycycline 100 mg daily is also used for malaria prophy-
laxis in many endemic countries. In a recent United Nations
peacekeeping deployment to East Timor, a group of islands
within the Malaysian archipelago, 22 of 135 (16%) Austra-
lian troops exhibited phototoxic reactions to doxycycline
100 mg daily. This study showed a high percentage of
phototoxic reactions to a relatively low dose of doxycycline.
UV intensity is primarily determined by factors such as solar
angle, latitude, season, ozone levels and cloud cover. As East
Timor is located close to the equator and experiences a sunny
climate throughout the year, the resultant UV exposure is
high. This may account for the high incidence of phototoxic
eruptions compared with other studies that were conducted
within the Northern hemisphere.1,2 Clinically, the phototoxic
reactions resembled exaggerated sunburn with diffuse erythe-
matous plaques more pronounced on sun-exposed areas such
as the face, neck and dorsum of hands. The fact that troops
did not experience sunburn prior to deployment at the very
similar latitudes, comparable exposure times and photopro-
tective methods, but experienced continued and pronounced
sunburn while doxycycline was prescribed, suggested that
the reactions were phototoxic in nature.
What was alarming was the fact that the sunscreen used
by the troops did not prevent photosensitive individuals from
sunburn. Most of the troops in the study were well educated
and motivated in the frequent and adequate use of sunscreen,
which was in constant supply throughout the 3-month
deployment. The sunscreen type used by all the troops
throughout this deployment was a sun protection factor 15
product that contained the following active ingredients: octyl
methoxycinnamate 7Æ5%, octyl salicylate 4% and oxybenzone
3%.
Oxybenzone is a UVA-absorbing benzophenone commonly
found in many broad spectrum sunscreens. It constitutes the
UVA-absorbing component of the sunscreen and partially
absorbs UVA radiation up to 340–360 nm.4,5 As phototox-
icity of tetracycline is mediated in the long wavelength of the
UVA spectrum, sunscreens containing oxybenzone as the
primary UVA absorber are ineffective for preventing sunburn
reactions as the phototoxic wavelengths lie outside the
photoprotective wavelengths.
However, there are more effective UVA photoprotectors on
the market that offer protection well into the UVA1 spectrum
(Table 1). Dibenzoylmethane derivatives offer protection up
to 400 nm; however, they may be irritant and photolabile.6
Newer chemicals that are photostable and offer longwave
UVA protection include terephthalylidene dicamphor sul-
phonic acid and drometrizole trisiloxane.
Physical blockers such as titanium dioxide are also effective
in UVA protection. Formulation trends of reducing particle
size, however, shift UV reflection from long wavelengths to
shorter wavelengths, effectively rendering titanium dioxide as
a UVB sunscreen, with less activity in the UVA range. Zinc
oxide has a flatter response across the UV range and thus
offers greater UVA protection.
Dermatologists frequently prescribe doxycycline and other
tetracyclines. The results of this study show a high rate of
phototoxic reactions at a low dose of this drug. We have been
aware of the phototoxic potential of this group of drugs for
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many years; however, we are now better equipped to offer
effective protection. While the sunscreen used in this
deployment prevented sunburn reactions in the UVB range,
it was ineffective in preventing phototoxic reactions to
doxycycline.
Not only is there an important need for correct use of
sunscreen by the user, but also choice by the physician of the
right sunscreen for the job is paramount in providing effective
photoprotection.
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Cold urticaria responding to systemic ciclosporin
SIR, A 69-year-old-woman presented with acquired immedi-
ate cold contact urticaria of 3 months’ duration, character-
ized by a weal and flare reaction to contact with anything
cold, including her lips when she had cold food. She was
severely disabled by the condition and was unable to leave
her house without having a widespread rash on the face,
trunk and limbs. General examination was otherwise unre-
markable and laboratory tests including full blood count,
immunoglobulins, cold agglutinins and cryoglobulins were
all normal or negative. Over the course of 1 year, the
following treatments were instigated without success: lorat-
adine, chlorpheniramine, fexofenadine, hydroxyzine, cetiri-
zine, double dose cetirizine, combined with ranitidine on a
regular (daily) basis and short courses of oral prednisolone.
In view of the disability, 10 months ago our patient was
commenced on ciclosporin 125 mg twice daily (just under
3 mg kg)1 daily). Within 1 week she noted an improvement
such that she was able to leave the house. Four weeks into
treatment, lesions were only appearing on the hands and feet
and the dose of ciclosporin was reduced to 100 mg twice
daily (2Æ25 mg kg)1 daily). The dosage was dropped
4 months into treatment to 75 mg twice daily (1Æ7 mg kg)1
daily). She has remained in remission on this dose with no
side-effects to date and is able to continue a normal pattern of
life with minimal recurrence of weals on the extremities only.
Cold urticaria is a rare condition characterized by weal and
flare that is triggered by cold, either by direct contact with
cold objects or by lowering of core body temperature.1
Patients may suffer considerable handicap as a result of their
symptoms. Treatment is often a challenge and many patients
fail to respond to the first-line treatments of oral antihista-
mines including combination H1 and H2 antihistamines.
Short-term therapy with oral corticosteroids may partially
suppress the symptoms temporarily,2 but it was unsuccessful
here. Desensitization may be helpful but is time-consuming
and may be only partially successful.1
Chronic urticaria has been shown to respond to ciclosporin
in a randomized controlled trial.3 We are not aware of any
published reports of acquired cold urticaria responding to
ciclosporin. We believe further studies are warranted to assess
the efficacy of ciclosporin in this potentially severely incapa-
citating condition.
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Table 1. Ultraviolet (UV) absorbers that provide protection into the



















butylphenol (MBBT, Tinasorb M)
290–400
2 1 4 C O R R E S P O N D E N C E
 2003 British Association of Dermatologists, British Journal of Dermatology, 149, 193–227
3 Grattan CE, O’Donnell BF, Francis DM et al. Randomized double-
blind study of cyclosporin in chronic idiopathic urticaria. Br J
Dermatol 2000; 143: 365–72.
Severe bullous drug eruption due to sibutramine
(Reductil)
SIR, Sibutramine (Reductil; Abbott Laboratories) is a new
centrally acting weight management drug, devoid of
amphetamine-like abuse potential, which inhibits the neur-
onal reuptake of serotonin and norepinephrine. Structurally
it is designated N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-meth-
ylbutyl}-N,N-dimethylamine hydrochloride monohydrate.
The primary and secondary pharmacologically active amine
metabolites induce weight loss by enhancing satiety and by
reducing the decline in energy expenditure during weight
loss. The common adverse reactions include headache, dry
mouth, insomnia, constipation, and increase in heart rate
and blood pressure.1 We report a new adverse reaction in a
patient in whom sibutramine caused the unusual complica-
tion of erythema multiforme-like bullous drug eruption.
A 19-year-old Chinese woman with a body mass index of
24 kg m)2 presented with fever, erosive stomatitis and an
erythematous targetoid cutaneous eruption. She had no
significant past medical history, and had no history of a
preceding viral infection. Two weeks prior to admission, her
general practitioner had prescribed her sibutramine 10 mg
daily, for weight reduction. She ingested the drug on the day
of the consultation, and then on the third, fifth and seventh
days after the visit. After the third dose, she developed
urticarial plaques over the dorsum of her hands and feet. Two
days later similar lesions appeared over the trunk, some of
which developed blisters. She consulted a traditional Chinese
physician who prescribed traditional Chinese medication on
the presumptive diagnosis of varicella. The rash continued to
spread extensively over the next 2 days.
On examination, the patient had a cutaneous eruption
consisting of erythematous and purpuric targetoid papules and
plaques over her trunk and limbs. Some of the lesions displayed
a central bulla (Fig. 1a). She had erosions and crusting over
her lips as well as ulcers affecting the buccal mucosa and soft
palate. However, her conjunctivae and genitalia were unaf-
fected. Her vital signs were stable, and the respiratory,
cardiovascular and abdominal systems were unremarkable.
A full blood count showed a raised white cell count of
13Æ4 · 109 L)1 with significant eosinophilia (1Æ2 · 109 L)1).
Renal and liver function tests were normal. Levels of C3 and
C4 were normal, and antinuclear antibody was absent.
Tzanck smear of a bulla did not demonstrate any multinu-
cleate giant cells. Serological tests for herpes simplex and
varicella infections were negative, and culture for herpes
simplex virus was negative. Skin biopsy from a bulla on the
right thigh showed subepidermal bullae with eosinophils, red
cell extravasation, and a superficial perivascular infiltrate
consisting of eosinophils and lymphocytes. The epidermis was
oedematous but keratinocyte necrosis was absent (Fig. 1b).
These findings were consistent with a drug eruption. The
patient was treated with oral prednisolone, and she improved
substantially by the fourth day of admission.
Our patient had a bullous drug eruption simulating
erythema multiforme. As the eruption had occurred before
the patient ingested traditional Chinese medicine, the only
offending drug was sibutramine. Because of the rare occur-
rence of this adverse reaction, an extensive search of the
literature and of the database of the drug manufacturer,
Abbot Laboratories, was made. However, no similar adverse
event has been reported. For comparison, we examined the
side-effects of a drug with a similar mechanism of action.
Venlafaxine, although structurally different from sibutram-
ine, is an antidepressant that inhibits neuronal serotonin and
norepinephrine reuptake. It is designated (R ⁄ S)-1-[(2-dimeth-
ylamino)-1-(4-methoxyphenyl)-ethyl] cyclohexanol hydro-
chloride. Included in its list of side-effects is erythema
multiforme.2 In an open-label study conducted to assess
patient acceptance and safety of venlafaxine in 58 geriatric
patients, one patient developed a rash that was judged to be a
serious drug-related side-effect. However, it resolved without
medical sequelae after venlafaxine was discontinued.3
Figure 1. (a) Targetoid eruption with central bulla over the trunk
and left forearm. (b) Subepidermal bullae containing eosinophils, red
cell extravasation and a superficial perivascular infiltrate consisting of
eosinophils and lymphocytes. The epidermis was oedematous but
keratinocyte necrosis was absent (haematoxylin and eosin; original
magnification ·100).
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This is the first report of a patient with a severe bullous
eruption related to sibutramine. When treating patients with
obesity, physicians should be familiar with this new drug, its
indications for prescription, and its rare but potentially severe
adverse effects.
B . K . G o h
P . P . L . N g
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Unusual, rapidly growing ulcerative genital mass
due to herpes simplex virus in a human immuno-
deficiency virus-infected woman
SIR, Herpes simplex virus (HSV) type 2 infection is common in
human immunodeficiency virus (HIV) type 1-infected sub-
jects, and generally causes classical vesicular herpetic genital
lesions1 with several recurrent episodes,2 sometimes severe
and associated with extensive genital ulcerations and pro-
longed viral shedding.3 Bacterial or fungal superinfections
may occur.3
We report an HIV-infected woman with a history of
recurrent genital HSV 2 infection who developed a rapidly
growing ulcerative genital mass while on highly active
antiretroviral therapy (HAART). A 39-year-old HIV+ woman
with a previous history of severe immune depression [CD4
cell count 7 mm)3 in 1996, when she had cytomegalovirus
(CMV) retinitis] presented to us in June 2000 with a 10-day
history of a painful, nonulcerative mass of the left labium
majus extending to the perianal region. The left inguinal
lymph nodes were swollen and ultrasound showed multiple
enlarged hypoechogenic lymph nodes. For the previous
14 months she had been on a triple antiretroviral regimen
consisting of stavudine, lamivudine and nevirapine. Her CD4
cell count was 880 mm)3 (22Æ7% of total lymphocytes), and
HIV RNA was < 50 copies mL)1 (Chiron Quantiplex 3.0
assay; Chiron, Emeryville, CA, U.S.A.). The patient had had a
primary genital herpetic infection in 1990 and, due to
periodic episodes of recurrence, had been on prophylaxis with
oral aciclovir 800 mg daily since 1997. On the presumptive
diagnosis of a bacterial superinfection presenting as a genital
mass, the patient was treated empirically with amoxi-
cillin ⁄ clavulanate for 15 days without any improvement.
One month later a biopsy of the mass was performed: tissue
cultures for viruses (HSV 1 and 2, CMV and varicella-zoster
virus), fungi, bacteria and mycobacteria (Mycobacterium
tuberculosis and atypical mycobacteria) were negative, as
were serological tests for syphilis and Cryptococcus neoformans.
Histology showed a chronic dermal and hypodermal
inflammatory infiltrate accompanied by pseudoepithelioma-
tous hyperplasia with multinucleated giant epithelial cells,
which suggested herpesvirus infection. Immunohistochemis-
try was negative for human papillomavirus (HPV) and for the
CMV immediate early nonstructural antigen of 72 kDa, but
was positive for HSV 2 using rabbit anti-HSV antibodies
obtained using antigens prepared by sonication and extraction
of HSV 2-infected rabbit cornea cells (Dako LSAB; Dako,
Carpinteria, CA, U.S.A.); all the virus proteins are present in
the antigens. In situ hybridization failed to demonstrate HPV
6, 11, 16, 18, 31, 33 and 51. Polymerase chain reaction
(PCR) for HPV was performed using three sets of PCR primers
for the L1 open reading frame (ORF) and two sets for E6 ⁄ E7
ORFs. HPV DNAs in tissue specimens were amplified using
PCR primer pairs LIC1 and LIC2 ⁄ L1C2M, MY09 and MY11,
GP17 and GP18, p U-1M-L and p U-2R, and p U-1 M-L and p
U-2R-N. Use of PCR failed to reveal HPV DNA in the specimen.
The mass was surgically removed in September 2000 and
the patient subsequently treated with intravenous foscarnet
40 mg kg)1 three times daily for 20 days, on the presumptive
diagnosis of an aciclovir-resistant HSV 2 infection. Intraven-
ous cidofovir 5 mg kg)1 was administered once every fort-
night as maintenance therapy.
In December 2000 the patient returned because of the
reappearance of a similar genital mass, at the same site,
accompanied by left inguinal swelling. Perianal and inguinal
ultrasound showed a solid mass with multiple homolateral
enlarged hypoechogenic lymph nodes. In February 2001 a
biopsy of a left inguinal lymph node revealed only nonspecific
lymphadenopathy. The genital mass grew rapidly in spite of a
new cycle of antiviral therapy with intravenous foscarnet
40 mg kg)1 three times daily for 3 weeks and despite a high
CD4 cell count (644 mm)3, 25% of total lymphocytes) and
undetectable HIV RNA. At the end of April 2001 the mass
had a major axis of 5 cm and had a verrucous appearance
(Fig. 1a). It was again surgically removed at the beginning of
May and intravenous aciclovir 10 mg kg)1 was administered
three times daily for 3 weeks. Tissue cultures for bacteria,
mycobacteria and fungi were negative while viral cultures
were positive for HSV 2, and the isolate did not exhibit
resistance to aciclovir or foscarnet on antiviral susceptibility
testing. A new histological examination of the mass demon-
strated a cutaneous, vegetative, ulcerative lesion character-
ized by pseudoepitheliomatous hyperplasia with severe
intracellular oedema, condensation of nucleoplasm in steel-
grey coloured nuclei with multinucleated cells and intranu-
clear inclusions, and a dense dermal infiltrate of mixed acute
and chronic inflammatory cells extending into an area of
granulation tissue at the base of the ulcer (Fig. 1b). HPV and
CMV were negative by immunohistochemistry, and in situ
hybridization and PCR did not reveal HPV. An immunophen-
otypic analysis of viral antigens was positive for HSV 1 (using
rabbit anti-HSV antibodies obtained using antigens prepared
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by sonication and extraction of HSV 1-infected rabbit cornea
cells; Dako LSAB) and HSV 2 and negative for HPV and
Epstein–Barr virus (EBV). This latter analysis was performed
on formalin-fixed paraffin-embedded tissue sections by in situ
hybridization using fluorescent-conjugated EBV-encoded
RNA probes complementary to the two nuclear RNAs
encoded by EBV. From May 2001 no recurrences of genital
herpes have been observed on the same antiretroviral
regimen and on oral aciclovir 800 mg daily.
This report is the first description of an ulcerative mass of
the genitalia in an HIV 1-infected woman which was likely to
have been induced by HSV 1 and ⁄ or 2, although a definite
causative association cannot be proved as it cannot be
excluded that the presence of the active viral infection
occurred secondary to the proliferative mass. Assuming that
HSV was the stimulus for the tissue growth, this case adds to
the previously described atypical manifestations of HSV
infections in HIV-infected individuals.4,5 The detection of
both HSV 1 and HSV 2 proteins by immunohistochemistry in
the second excision specimen contrasts with the positivity of
culture only for HSV 2; it may be that either the antibody
preparations used for detection of HSV 1 and 2 proteins lack
specificity or that HSV 1, although present, failed to grow in
culture. PCR analysis of the tissue samples should have solved
this critical issue, but unfortunately we did not perform this
type of analysis.
A similar clinical case (large scrotal lesion) has recently
been reported in a man6 but, in contrast with our patient, he
was profoundly immune suppressed. In patients with HIV
disease the degree of immune suppression strongly correlates
with the HSV reactivation rate and the severity of disease.7–9
Severe mucocutaneous HSV infections are thought to occur
only when cellular immunity is markedly impaired.8 At
variance with this notion, our patient had a well-preserved
CD4 cell count.
Others have shown that patients on HAART have
restoration even of immune responses specific to HSV, as
early as 4 weeks after starting treatment.10 Perhaps in our
patient a deficient restoration of HSV-specific immune
responses induced the unusual severity and persistence of
the lesions.
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Figure 1. (a) Ulcerative genital mass of the left labium majus. (b)
Ulcerative lesion with dermal infiltrate of polymorphonuclear leuco-
cytes, vascular proliferation and multinucleated cells with nuclear
inclusions (haematoxylin and eosin; original magnification ·40).
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Share of research output in dermatology:
a quantitative ranking
SIR, The share of published research seems to be an
important indicator for evaluating each country’s research
activity in a particular field. On the basis of this principle,
top-ranking countries in the biomedical field as a whole
and also separately for different categories have been
reported.1–10 A study also reported the ranking of different
countries in dermatology based on articles and citations
using data from the period 1981–1996.11 However, ranking
based on the last decade’s data, number of randomized
controlled trials (RCTs) originating from a country, and the
relationship of research productivity of a country with the
impact factor of a journal has not been examined yet. This
study was conducted to determine the top-ranking countries
in the field of dermatology with respect to research
productivity and generation of RCTs, along with the trend
over time. In addition, the relationship of research produc-
tivity of a country with the impact factor of journals was
also examined.
Twenty top-ranking journals, according to impact factor,
were selected from a total of 38 journals listed in the
category of Dermatology and Venereal Diseases set by
Institute for Scientific Information.12 The selection criteria
were that the journal: (i) is available in the Medline
database, (ii) covers a broad range of dermatological and
related fields, and (iii) publishes articles in English. The
Medline database was searched in October 2002 to obtain
information on the country affiliation of journal articles
published in the selected journals during the period 1991–
2000. Only journal articles were included in the analysis, i.e.
letters, correspondence, editorials, book reviews and news
items were excluded. In the first instance, one of the authors
(M.R.) identified all the selected journals in the Medline
database and downloaded the data on author affiliation,
name of the journal, publication type and publication year.
Next, these data were transformed into an Excel spreadsheet.
After that, appropriate automatic coding procedures were
used to perform descriptive and other specific statistics. We
used the Internet to identify country affiliations when this
information was not available from Medline. Research
productivity of a country was judged by the number of
articles affiliated to that country through the corresponding
author. The proportion of contributions made by each of the
countries during the last decade was ranked in descending
order. Shares of 20 top-ranking countries were also gener-
ated for each year (1991–2000) to examine the time trend.
Nonparametric tests for trend were conducted to elicit any
significant change over time. In addition, the relationship
between the contribution of each of the 10 top-ranking
countries and journal impact factor was fitted into a cross-
sectional time-series linear model and estimated using
generalized least squares. In this model, the percentage
contribution of each country to each journal in a year was
considered as a dependent variable and the impact factor of
each individual journal in a particular year was considered
as an independent variable. Five-year data (1996–2000)12
were fitted into the model, as data on impact factor before
that period were not available from the available sources. We
performed all the statistical procedures using STATA statis-
tical software.13 All tests of significance were two-tailed and
values of P £ 0Æ05 were considered significant.
In total, 28 201 articles were published during 1991–
2000 in the selected journals (nine from the U.S.A. and 11
from Europe). Affiliation data were available for 27 881
(98Æ9%) articles. Table 1 shows 20 top-ranking countries in
terms of share of total articles. The U.S.A. contributed 29Æ7%
of the total articles and ranked top among all the countries,
followed by the U.K. (11Æ7%), Japan (9Æ5%), Germany (7Æ7%)
and Italy (5Æ5%). In time trend analysis, the share of articles
by the U.S.A. (P ¼ 0Æ02) and Denmark (P ¼ 0Æ04) decreased
significantly in the last decade (Table 1). On the other hand,
Japan (P ¼ 0Æ02), Germany (P ¼ 0Æ01), Finland (P ¼ 0Æ04),








(n ¼ 28 201)
U.S.A.fl 36Æ8 25Æ1 29Æ7
U.K. 11Æ7 12Æ1 11Æ7
Japan› 8Æ2 10Æ4 9Æ5
Germany› 5Æ8 9Æ7 7Æ7
Italy 4Æ9 5Æ3 5Æ3
France 3Æ7 3Æ6 4Æ3
Spain 2Æ5 3Æ5 3Æ4
Netherlands 4Æ4 2Æ1 2Æ9
Sweden 3Æ0 2Æ4 2Æ5
Switzerland 1Æ1 1Æ9 2Æ0
Denmarkfl 2Æ5 1Æ4 1Æ8
Canada 1Æ6 1Æ6 1Æ7
Finland› 1Æ2 1Æ6 1Æ6
Belgium 0Æ8 1Æ4 1Æ5
Israel 1Æ4 1Æ4 1Æ4
Australia 1Æ3 1Æ6 1Æ3
Austria 1Æ1 1Æ1 1Æ2
South Korea› 0Æ5 1Æ7 1Æ0
India 0Æ8 1Æ4 0Æ9
Turkey› 0Æ1 1Æ3 0Æ6
Other countries› 6Æ6 9Æ8 8Æ1
Ranking based on total number of articles published during 1991–
2000. (Data did not sum up to 100%, because the affiliations of about
1Æ1% articles were not available from the Medline database.) ›Share
of articles went up significantly over time. flShare of articles went
down significantly over time. Journals selected (according to impact
factor in descending order): Journal of Investigative Dermatology, Sex-
ually Transmitted Diseases, Archives of Dermatology, British Journal of
Dermatology, Journal of American Academy of Dermatology, Sexually
Transmitted Infections, Experimental Dermatology, Melanoma Research,
Acta Dermato-Venereologica, Archives of Dermatological Research, Journal
of Dermatological Science, Dermatologic Clinics, Contact Dermatitis,
Journal of the European Academy of Dermatology and Venereology, Der-
matology, International Journal of Dermatology, European Journal of
Dermatology, Clinical and Experimental Dermatology, Pediatric Derma-
tology, Clinical Dermatology.
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South Korea (P ¼ 0Æ01) and Turkey (P ¼ 0Æ01) showed a
significant upward trend.
In total, 883 RCTs (3Æ1% of total articles) were published in
the selected 20 journals without any positive trend over the
period of time (P ¼ 0Æ28). The U.S.A. also ranked top (31Æ8%)
in generating high-grade evidence (RCTs) followed by the U.K.
(13Æ0%) (Fig. 1a). Among the top-ranking countries in derma-
tology, Japan contributed only 10 RCTs (15th in the world)
while Spain had only five (18th in the world) in this field. No
countries showed a significantly positive trend for RCTs over
the period of time. Journal-wise, the Journal of American
Academy of Dermatology published most of the RCTs (25Æ0%)
followed by the British Journal of Dermatology (18Æ9%) (Fig. 1b).
The U.S.A.’s contribution was more to the journals with
high impact factor (b ¼ + 7Æ5, P ¼ 0Æ001) while the opposite
was true for Spain (b ¼ )1Æ0, P ¼ 0Æ01) as elicited by cross-
sectional time-series linear model using generalized least
squares. Other top-ranking countries did not show any
significant relationship.
Although American publications dominate the biomedical
literature, normalizing the proportion of contribution by
population will certainly change the order in top-ranking
countries. In a study where all journal articles in Medline
were analysed for country affiliation, Sweden ranked top
when the proportion of contribution was normalized by the
population size, and the U.S.A.’s position slipped to seventh.2
Small European nations and Israel remained in the upper part
of the top-ranking countries when the contributions from
different countries were normalized by the size of the
population. In this study, we preferred to rank the countries
according to the total contribution to identify who is
contributing how much in dermatology.
There is no doubt that the U.S.A. leads all other countries
in productivity of medical research.1–11 However, its share for
research articles in dermatology decreased from 36Æ8% in
1991 to 25Æ1% in 2000. The U.S.A.’s contribution, as elicited
in our study, was lower (30%) than that reported for the
articles published in 24 dermatology journals during 1981–
1996 (36%).11 The U.S.A. showed a similar negative trend
for basic science, general medicine, infectious disease, nuclear
medicine, ophthalmology and epidemiology research output
in the last decade.1,5–7,9 One study also reported that the
U.S.A.’s contribution during the 1980s had also shown a
downward trend based on a group of journals.14 This feature,
along with our study, implies that the downward trend in the
U.S.A.’s contribution is a continuous phenomenon. On the
other hand, the U.K.’s contribution was almost similar (11%
in 1981–1996 and 11Æ7% in 1991–2000). Collective contri-
bution from the top 10 countries decreased slightly from 82%
during 1981–199611 to 79% as found in our study for
1991–2000 data, which means that other countries are
catching up gradually in research in dermatology.
Regarding RCTs, all top-ranking countries contributed
almost proportionately except Japan and Spain. Appropriate
initiatives in the respective countries are necessary to
increase the number of RCTs from these two countries.
There are some limitations of this study. Firstly, although
most of the publications had single country affiliation, some
studies were conducted in joint collaboration by mixed teams
of local and international researchers and only corresponding
authors’ affiliations were included as the origin of research in
the Medline database. Secondly, some articles on dermatology
might have been published in other clinical journals. If these
factors were taken into account, the actual number for
research output for each country would be higher than the
results we obtained. However, these situations are not
confined to a particular country, but rather are related to
all the countries. Thus, the absolute number of articles shown
here does not reflect the true situation in terms of research in
dermatology, but estimates on the proportion of contribution
should not be far from the real situation.
In conclusion, our analysis elicits 20 top-ranking countries
for research output in the field of dermatology and reveals
Figure 1. Top-ranking countries (a) and journals (b) with the
number of randomized controlled trials. JAAD, Journal of American
Academy of Dermatology; BJD, British Journal of Dermatology; AD,
Archives of Dermatology; IJD, International Journal of Dermatology; D,
Dermatology; ADV, Acta Dermato-Venereologica; STD, Sexually Trans-
mitted Diseases; JID, Journal of Investigative Dermatology.
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that the shares of the U.S.A. and Denmark decreased while
that of Japan, Germany, Finland, South Korea and Turkey
increased in the last decade.
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Efficacy of fumaric acid ester monotherapy in psoriasis
pustulosa palmoplantaris
SIR, Psoriasis pustulosa palmoplantaris (PPP) considerably
affects the quality of life because of its location, its chronic
course and its poor response to treatment. Treatment
modalities include photochemotherapy, systemic retinoids,
methotrexate and immunosuppressive drugs such as ciclosp-
orin and mycophenolate mofetil,1–3 which are frequently
associated with serious side-effects. Fumaric acid esters (FAE)
have been shown to be safe and effective in severe plaque
psoriasis.4–6 Further observations indicate FAE effectiveness
even for those complicating forms of psoriasis such as
psoriatic arthropathy, nail involvement, erythrodermic and
generalized pustular psoriasis4,5 which are still difficult to
treat. However, the efficacy of FAE on isolated PPP has not
been explored so far. This report describes the results of an
open prospective clinical study with the aim of evaluating the
efficacy of FAE monotherapy in patients who suffered from
isolated PPP.
Thirteen patients (eight female, five male) from 25 to
78 years of age (mean 52Æ5 years) suffering from isolated
PPP were enrolled for treatment with FAE tablets [Fuma-
derm, containing 120 mg dimethylfumarate (DMF) per
tablet] for a period of 24 weeks. Patients were seen every
4 weeks for examination and laboratory investigations. The
FAE dose was individually adjusted up to a maximum dose of
720 mg (six tablets) per day. Patients who had received
active antipsoriatic treatment within the previous 3 weeks
were excluded. During this study no accompanying antipso-
riatic therapy was allowed except bland topical treatment
with petrolatum either without or with 5% salicylic acid. A
modified Psoriasis Area and Severity Index (PASI) called
Psoriasis pustulosa palmoplantaris Area and Severity Index
(PPPASI) was developed (Table 1). The score includes
pustules and erosive lesions. A maximum score of 26 can
be reached in the PPPASI. The PPPASI score was evaluated
for each extremity separately (Table 1) and P-values were
calculated with a t-test using the Microcal Origin program
(OriginLab, Friedrichsdorf ⁄ Ts, Germany).
All 13 patients were treated for at least 8 weeks. Two
patients (15Æ4%) dropped out after 9 and 11 weeks because of
gastrointestinal complaints and increasing lipase values,
respectively. Three patients (23Æ1%) discontinued the study
after 8 and 12 weeks because of worsening or insufficient
clinical response. A total of eight patients completed the study
whose mean dose of FAE was 585 mg per day (SD ± 197Æ05).
Side-effects were flushing (n ¼ 6), gastrointestinal complaints
(n ¼ 9), lymphopenia (n ¼ 3), increased liver enzymes
(n ¼ 3) and increased lipase (n ¼ 1). Following dose reduc-
tion side-effects were tolerable in most patients.
Results were similar for palmar and plantar lesions. At
week 8 two patients had a decrease of PPPASI score of more
than 70%, three patients had a decrease between 30% and
70% and in six patients disease was stable with a decrease or
increase of PPPASI less than 30%. In one patient palmar
lesions increased to PPPASI 30–70% and in another there
was an increase of more than 70%.
The palms of the eight patients who were treated for
24 weeks showed a decrease of PPPASI score of more than
70% in two patients, two patients showed a decrease between
30% and 70% and in four patients disease was stable with a
decrease or increase of less than 30%. For plantar lesions
there was an decrease of PPPASI of more than 70% in three
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patients, a decrease of between 30% and 70% in three
patients, one had stable disease with PPPASI score decreasing
or increasing less than 30% and one patient a score
worsening by more than 70%.
The PPPASI after 8 weeks in the entire patient group
dropped significantly from 12Æ5 to 9Æ4 (P ¼ 0Æ04) for palmar
involvement and to a lesser degree from 14Æ1 to 11Æ1
(P ¼ 0Æ11) for the soles (Fig. 1). In the eight patients who
completed the study after 24 weeks, PPPASI score showed a
statistically significant reduction of involvement of both
palmar and plantar skin from an initial score of 14Æ3 to 7Æ3
(palms, P ¼ 0Æ004) and from 13Æ00 to 7Æ2 (feet, P ¼ 0Æ03)
(Fig. 2).
The time to relapse was not studied in this trial. The
reasons are that our severely affected patients had a previous
history of psoriasis pustulosa palmoplantaris of more than
6 months. Therefore five of eight patients wanted to continue
with successful FAE therapy after completing the study period
of 24 weeks.
The results of this study show for the first time that FAE
monotherapy is an effective treatment for psoriasis pustulosa
palmoplantaris. The newly developed PPPASI score was an
easy and valuable new tool. In this trial we found a
reduction of PPPASI score of an average of 49% for palmar
and 44% for plantar lesions at 24 weeks, i.e. an improve-
ment of 75% at week 24. This was less improvement than
in the German multicentre study, which revealed a mean
reduction in the PASI score of 80% during a 16-week
period,5 suggesting that FAE monotherapy of PPP is not as
effective as FAE therapy in other clinical types of psoriasis.
On the other hand, other authors showed a decrease of the
PASI score by 50% and a clinical improvement in 70% of
the patients after 16 weeks of treatment4 and an improve-
ment in approximately 50% of patients receiving FAE for at
least 3 months.7,8 Our results also emphasize the need for a
long-term treatment when giving FAE, which is typical for
this drug.
In our clinical trial high doses of FAE were necessary. The
mean dose of the eight patients who completed this trial was
584Æ4 mg FAE per day. Five of them (62Æ5%) required the
maximum dose of 720 mg FAE per day. In two of these
patients the dose could subsequently be reduced while
maintaining the good therapeutic result. In one patient only
two tablets FAE per day were necessary to achieve a
therapeutic response. Only 46% of the patients with psoriasis
vulgaris required the maximum dose of six tablets FAE per
day.5
The side-effects consisted of flushing (46%) and of
gastrointestinal complaints (69%) including diarrhoea and
stomach ache, lymphopenia (23%) and increases of liver
enzymes (23%). In agreement with previous studies side-
effects were frequent, but could be controlled by dose
reduction and were of transient nature. Individual adjust-
ment of the dose of FAE is advisable to avoid severe side-
effects. Gastrointestinal complaints usually disappear with
prolonged use of FAE.8
Lymphopenia, which occurred in three patients (38%) in
our trial, has also been reported in previous studies using
FAE.1 After discontinuation of the FAE treatment lymphope-
nia usually resolves completely.6,9 In our trial three patients
showed slightly increased liver enzymes. None of these
patients had to discontinue the therapy because of this side-
effect. Furthermore, it has been reported that increased liver
enzymes normalized after reduction of the daily dosage.8 To
finally confirm our findings, further controlled clinical trials
are required in PPP.
Palmar right side Palmar left side Plantar right side Plantar left side
Extent 0–6 0–6 0–6 0–6
Desquamation 0–4 0–4 0–4 0–4
Erythema 0–4 0–4 0–4 0–4
Erosion 0–4 0–4 0–4 0–4
Infiltration 0–4 0–4 0–4 0–4
Pustules 0–4 0–4 0–4 0–4
Total 0–26 0–26 0–26 0–26
Table 1. Psoriasis pustulosa palmoplantaris
area and severity index
Figure 2. Mean total PPPASI scores after 24 weeks (n ¼ 8).
Figure 1. Mean total PPPASI scores of all patients after 8 weeks
(n ¼ 13).
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Granulomatous blepharitis successfully treated
with tranilast
SIR, The complete triad of Melkersson–Rosenthal syndrome is
orofacial swelling, facial palsy and lingua plicata. As a
symptom on its own, orofacial swelling may occur in several
sites such as the lips, cheeks, chin, labial mucosal surfaces
and eyelids. Granulomatous blepharitis, which is a sympto-
matic variant of Melkersson–Rosenthal syndrome, is charac-
terized clinically by diffuse, insensitive but soft or firm
swelling of the eyelids and shows a histological noncaseating,
epithelioid granulomatous inflammation.1,2 N-[3,4-dimeth-
oxycinnamoyl]-anthranilic acid (tranilast) inhibits the release
of some chemical mediators by mast cells, and is widely used
in Japan to treat patients with bronchial asthma, atopic
dermatitis, allergic rhinitis, keloid and hypertrophic scars.
Several case reports have demonstrated that tranilast is an
effective treatment for Melkersson–Rosenthal syndrome and
granulomatous cheilitis, a related symptomatic variant
involving the lips.3–5 Here we report the first case of
granulomatous blepharitis successfully treated with tranilast.
A 69-year-old Japanese man with a 4-month history of
persistent, asymptomatic eruptions on his right eyelid visited
our hospital. Physical examination revealed oedematous
erythema on his right eyelid with conjunctival hyperaemia
with some associated discharge (Fig. 1a). He had no sign of
facial palsy or a plicated tongue. An initial clinical diagnosis
of Quincke’s oedema was made, and the patient was first
treated with oral fexofenadine hydrochloride for 1 week,
which failed to improve his symptoms. A skin biopsy was
taken from the medial-most quarter of the right upper eyelid
with a 5-mm diameter dermal biopsy punch. The specimen
showed no pathological changes within the horny, or lower
epidermal layers, nor epidermal–dermal junction, although
there was remarkable oedema and dilated lymphatic capil-
laries with a diffuse infiltration of histiocyte-like cells inclu-
ding erythrophagocytic cells and mononuclear large cells
with a rich basophilic cytoplasm in the dermis and the
subcutaneous tissue (Fig. 2a,b). Immunohistochemical ana-
lysis demonstrated these histiocyte-like cells were CD68+
(data not shown).
Routine laboratory tests including liver and renal function
were within normal limits. Based on the clinical and
histological findings, we diagnosed this patient as suffering
from granulomatous blepharitis. As tranilast has been
reported to be effective in some cases of this condition,5 we
prescribed an oral dose of 300 mg daily for a 7-week period.
Three days after the start of this treatment, remarkable
improvement was observed both objectively and subjectively.
The swelling of right eyelid became dramatically reduced.
Four months after treatment withdrawal, no signs of any
recurrence were observed (Fig. 1b).
Tranilast has been used in the treatment of atopic derma-
titis because of its antiallergic action. It affects the membranes
of mast cells, resulting in the inhibition of release of chemical
mediators including the histamines and prostaglandins.6
Tranilast also inhibited collagen synthesis in scleroderma
fibroblasts to the same extent as normal fibroblasts. In keloid
fibroblasts, tranilast inhibited collagen production more than
normal fibroblasts, attesting to its therapeutic potential as an
antifibrotic drug.7 Recently, tranilast was also shown to be a
potent oral antiproliferative agent that inhibits the growth
and migration of vascular smooth muscle cells.8 Furthermore,
there have been several case reports of the successful
treatment of Melkersson–Rosenthal syndrome and granulo-
matous cheilitis with tranilast.3–5
Although the exact therapeutic mechanisms of tranilast in
resolving these conditions remain unclear, there is enough
evidence to suggest a hypothetical effector mechanism in
these diseases. In vitro experiments have shown that tranilast
directly inhibits the formation of multinucleated giant cells
from their precursor human peripheral monocytes.9 Tranilast
was also demonstrated to decrease interferon (IFN)-c and
interleukin (IL)-2 production from T-helper 1 cells of patients
with atopic dermatitis.10 Since IL-2 promotes macrophage
mutation through macrophage activating factor, macro-
phage chemotactic factor, and migration inhibition factor
production11 and in addition IFN-c activates macrophages by
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increasing intercellular adhesion molecule-1 expression,12 we
speculate that the inhibition of IFN-c and IL-2 production is a
possible tranilast therapeutic mechanism in granulomatous
pathology.
The aetiology of Melkersson–Rosenthal syndrome (and
granulomatous blepharitis) is unknown, and there is no
standard treatment for this disease. Although tranilast is only
currently available in Japan and Korea, the present case is the
first report of granulomatous blepharitis successfully treated
with this particular cytokine release inhibitor.
F . I w a o
D . S a w a m u r a
K . Y o k o t a
H . S h i m i z u
Department of Dermatology,
Hokkaido University Graduate School
of Medicine, North 15 West 7, Kita-
ku, Sapporo 060-8638, Japan
E-mail: mayamaya@viola.ocn.ne.jp
Figure 1. (a) Oedematous erythema on the right eyelid associated
with conjunctival hyperaemia and some discharge was observed just
before treatment. (b) Four months after the withdrawal of treatment
with tranilast.
Figure 2. (a) Histological examination showed a remarkable dermal
oedema with dilated lymphatic capillaries and a diffuse infiltration of
histiocyte-like cells including mononuclear large cells with a rich
basophilic cytoplasm (haematoxylin and eosin, original magnification
·100). (b) Erythrophagocytic cells were detected (haematoxylin and
eosin, original magnification ·200).
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Topical treatment of Netherton’s syndrome with
tacrolimus ointment without significant systemic
absorption
SIR, Netherton’s syndrome (NS) is a rare autosomal recessive
skin disease characterized by ichthyosis linearis circumflexa
(ILC), trichorrhexis invaginata and atopy. Mutations of the
secretory serine protease inhibitor Kazal type 5 gene
(SPINK5) are responsible for desquamation and epidermal
barrier dysfunction in NS by increased protease activity in the
upper stratum corneum.1 Cutaneous manifestations vary
from localized ichthyosis to severe and persistent erythroder-
ma which is often resistant to therapy.
Tacrolimus ointment is a topical immunomodulatory agent
successfully tested for the therapy of atopic dermatitis (AD).
Its exact mechanism of action in AD remains incompletely
understood, but the binding to a specific immunophilin
(FKBP12) inhibits the transcription and synthesis of several
proinflammatory cytokines in T cells.2 Application of 0Æ1% or
0Æ03% ointment to extensive areas of atopic eczema does not
lead to blood concentrations of more than 1Æ0 ng mL)1 in
adults3 and children,4 or does so only transiently.
Recently, Allen et al.5 reported a marked improvement of
NS ichthyosiform erythroderma in three children aged 3, 5
and 14 years using 0Æ1% tacrolimus ointment, but the blood
tacrolimus concentration reached immunosuppressive levels
when large areas were treated. Successful therapy with
tacrolimus of isolated ILC in a 20-year-old adult has been
described by Suga et al.6 but in their paper the blood
concentration was not monitored. We have evaluated the
efficacy and percutaneous absorption of tacrolimus in a
patient with particularly disfiguring erythrodermic NS who
was treated with progressively increasing applications of
tacrolimus ointment.
A 17-year-old girl who was born from consanguineous
parents had congenital ichthyosiform erythroderma, bamboo
hairs and food allergies. She also had a history of recurrent
bacterial conjunctivitis, otitis, vaginitis and chronic sinusitis.
The diagnosis of erythrodermic NS was confirmed by SPINK5
mutation analysis.7 She had not responded to previous
therapeutic attempts including topical corticosteroids, topical
vitamin D analogues, retinoids and antihistamines.
As an in-patient, our patient applied a thin layer of 0Æ03%
tacrolimus ointment twice daily to selected skin areas. The
treated surface was extended progressively, and was monit-
ored clinically and biologically. Full blood count, renal and
liver function as well as blood tacrolimus level were assessed
once weekly 12 h after the last application.
During the first month, the applications were limited to the
left half of her face. Approximately 0Æ5 mg of tacrolimus was
used daily. Our patient began to improve, as shown in
sequential photographs (Fig. 1a,b). Facial erythema, scaling
and pruritus were already less marked after 1 week on the
treated side, with a slight diffusion to the right half of the face.
After 4 weeks, the treated side of the face was nearly cleared.
The treatment was well tolerated except for some slight local
burning. Blood pressure, cell counts and chemistry profiles
remained within normal ranges. The blood tacrolimus
concentration was undetectable (laboratory threshold
< 3 ng mL)1) at all determinations.
During the second month, the applications were extended
to the whole face (1 mg tacrolimus daily), and improvement
continued in this region without notable adverse events. The
blood tacrolimus level remained below the detection thresh-
old. For the following 4 months, our patient continued
tacrolimus therapy on an out-patient basis with applications
to the whole face and one breast, corresponding to the use of
approximately 1Æ5 mg of tacrolimus daily.
Improvement of erythema was less marked on the breast
than it had initially been on the face, and at follow-up visits a
partial relapse was noted on the face that might have
corresponded to reduced therapeutic compliance. No adverse
effect was recorded and tolerance to treatment remained
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satisfactory. During the whole treatment we observed no
exacerbation of the known infections. The blood tacrolimus
concentration as determined by another laboratory 6 weeks
after the extension of applications to the breast was
1Æ6 ng mL)1. All other weekly blood determinations, per-
formed at the same laboratory, indicated undetectable drug
levels (laboratory threshold < 1Æ5 ng mL)1).
Tacrolimus therapy was discontinued 6 months after the
first application. Its therapeutic benefit persisted on the face at
4 months of follow-up, whereas an erythrodermic flare
occurred on the trunk.
Patients with NS have a significant risk of systemic
absorption after exposure to topically applied treatments
such as corticosteroids, paraffin from emollients, and tacrol-
imus.5 In all published cases of tacrolimus therapy for NS,
however, the topical immunomodulator proved effective.5,6
Allen et al.5 detected a decrease in blood tacrolimus concen-
tration when the treated surface area or application fre-
quency were reduced and when 0Æ03% ointment was used
instead of the 0Æ1% adult form.
Our case illustrates the efficacy and tolerability of treatment
with 0Æ03% tacrolimus ointment of limited, but progressively
increasing, skin areas of NS. To avoid systemic absorption, we
increased the applications progressively and treated less than
15% of the body surface, with regular monitoring of the blood
tacrolimus concentration. Our protocol enabled significant
limitation of percutaneous absorption. It offers a therapeutic
option in NS for the treatment of the most severely involved
areas under strict medical control.
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Figure 1. Clinical appearance (a) before tacrolimus therapy and (b)
after 19 days of topical treatment with 0Æ03% tacrolimus ointment
twice daily only on the left half of the face.
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Book review
Textbook of Facial Rejuvenation (2002). Edited by
Nicholas J Lowe. London: Martin Dunitz Ltd. Hardback,
406pp. ISBN: 1–84184–095–5. Price £125.95.
The last few decades have seen a marked shift of dermatol-
ogy into cosmetic treatment, in particular in the treatment of
the ageing skin. This multi-author textbook, edited by Profes-
sor N Lowe and a team of co-editors, has been put together to
guide the dermatologist and dermatological surgeon in the
range of treatment options which now may be selected and
combined to give the best possible facial appearance.
The main 28 chapters have been written by the most
experienced and often pioneering dermatologists in their
particular field. Broadly speaking it is divided into resurfacing
techniques such as peels and laser resurfacing, the use of
botulinum toxin, dermal fillers and hair transplant tech-
niques. Other chapters deal with hair transplantation or
removal, endoscopic surgery and digital photography. Each
chapter is written by an expert in its field with, inevitably, a
heavy predominance of authors from the United States, with
a smaller number of contributors from the United Kingdom
and Europe. At the end there are appendices giving patient
advice leaflets and consent forms which could be modified to
the individual practitioner’s needs.
Most of the chapters are extremely well illustrated with
generally excellent photographs. Detailed practical informa-
tion and advice is to be found in the appropriate chapters and
the text and layout of the book leads to easy and almost
addictive reading. Most chapters are well referenced although
in a few the references are little dated.
Given the very high quality maintained throughout this
book, any criticisms levelled at it must be seen as minor. The
combination treatment text box at the end of each chapter,
intent on linking various conditions with their potential
combined treatments and the relevant chapter reference, is
not all that helpful and this is perhaps this is compounded by
its dull grey background. A few references are incomplete
having been put down as being in press for 2000 or the
journal being omitted.
Generally, however, I have found this book to be extremely
attractive, easy to read, gives exceedingly good practical and
down-to-earth advice combined with excellent clinical pho-
tographs. These features combined with the fact that the
authors area all international authorities in their field, must
make this book one of the most authoritative works presently
available. Despite its expense, I really think that this book is a
must for anyone with a serious interest in facial rejuvenation
and this is one that I would recommend for personal purchase
as a day-to-day guide in cosmetic procedures and patient
information.
D a v i d J . E e d y
News and Notices
Twenty-fifth Annual Samuel J. Zakon Award in the
History of Dermatology
Papers are now being called for the twenty-fifth annual
Samuel J. Zakon Award in the History of Dermatology. This
competition is open to historians and dermatologists in
practice or training. Manuscripts should be submitted to
Mark C. Valentine. M.D., Chairman, Samuel J. Zakon
Award Committee, 3327 Colby Avenue, Everett, WA
98201, by 1 November 2003. Essays may relate to any
aspect of the history of dermatology not heretofore
published.
Both the Zakon Lectureship and Zakon Award are given in
memory of Dr Samuel J. Zakon, outstanding Chicago derma-
tologist and historian, by his children.
Paediatric Dermatology Course, Liverpool, UK
This clinical course is held annually in Liverpool and is aimed
at Specialist Registrars and recently appointed Consultant
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Dermatologists and Paediatricians. An important component
of the course is small group clinical teaching. Numbers
are limited to 12. The next two-day course will be held on
23 and 24 October. For further details contact:
Dr G Sharpe, Course Organiser, The University of Liverpool,
Dermatology Unit, Department of Medicine, UCD Building,
Liverpool, UK, L69 3GA. Tel: 0151 706 4030; Fax: 0151
706 5842; Email: lmf@liverpool.ac.uk.
11th Meeting of the European Society of Pigment Cell
Research
Gent, Belgium, 17–20 September 2003
The scientific programme will include invited lectures by
world-class speakers and six special lectures, some of which
will be presented by outstanding scientists not working in the
field. The clinical Satellite Meeting on Saturday is also the
official autumn meeting of the Royal Belgian Society of
Dermatology: prominent speakers will deliver state-of-the-art
lectures on the pathogenesis and treatment of pigmentation
disorders and Belgian dermatologists will present papers with
a focus on pigmentary disorders and melanoma.
Please contact the Meeting Secretariat: Tel: +31 (0) 40 285
2212; Email: info@mediscon.nl.
For further information see www.espcrgent2003.org/
Clinical Management of Children and Adults with
Epidermolysis Bullosa
23–24 October 2003
An international Symposium, to be held at Great Ormond
Street Hospital for Children, London WC1N 3JH.
Following the postponement of this meeting last year, we
are pleased to announce that it will now go ahead this year.
The focus of this symposium will be the multidisciplinary care
of patients with epidermylosis bullosa, and we are therefore
keen to welcome participants from all relevant disciplines.
The meeting is sponsored by DEBRA UK.
If you are interested in participating, please email Jill Hart-




Four fellowships of up to Eur 4500 each (for short exchange
periods) and one up to Eur 18 000 (for a long exchange
period) are given towards supporting a period spent in a
research laboratory or clinical department of a different
country in order to promote international collaboration.
Application forms for either type of grant may be requested
from the office of the Foundation by email: fond.r.tour-
aine@chu-stlouis.fr or at the following address: Fondation
René Touraine, Hôpital St Louis, Pavillion Bazin, 1, avenue
Claude Vellefaux, F-75475, Paris Cedex 10, France; Tel: +33
1 53 72 20 60; Fax: +33 1 53 72 20 61.
Deadline for applications by email or mail: 1 October 2003
Scientific Meeting 2003: T-cells and the skin immune
system
Friday 7 November 2003
Ministère de la Jeunesse, de l’Education nationale et de la
Recerche, 1, rue Descartes, 75005 Paris.
Invited speakers: H. Von Boehmer, A. Trautmann,
E. Shevach, E. Vivier, S. Beissert, M. Akdis, J. Prinz, H.
Bachelez.
Registration: Fondation René Touraine, Hôpital St Louis,
Pavillion Bazin, 1, avenue Claude Vellefaux, F-75475, Paris
Cedex 10, France; Tel: +33 1 53 72 20 60; Fax: +33 1 53 72
20 61; by email: fond.r.touraine@chu-stlouis.fr.
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